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Through somatic cell nuclear reprogramming (SCNT), differentiated cells may be 
indirectly reprogrammed into pluripotent stem cells by exposing their nuclei to an 
undefined amalgam of proteins present in the cytoplasm of an oocyte. Reprogramming 
via SCNT is rapid and efficient, and the resultant reprogrammed pluripotent stem cells 
are uniformly of “high quality” and are bona fide pluripotent cells, capable of efficient 
contribution of chimeric fetuses. On the contrary, when differentiated cells are directly 
reprogrammed into induced pluripotent stem cells (iPSCs) by overexpressing a defined 
set of pluripotency transcription factors, the pursuant reprogramming process is 
inefficient, slow, and rarely yields authentic pluripotent stem cells with the facility for 
tetraploid complementation. Hence, it is conceivable that oocyte may contain powerful 
factors that could augment the kinetic, efficiency and quality of iPSC reprogramming 
akin to that of SCNT. This project aimed to identify specific oocyte-expressed proteins 
that could potentiate the reprogramming of somatic cells into iPSCs by defined factors.  
Here, I demonstrate that the overexpression of oocyte-expressed TCL1 family 
member genes (TCL1 and TCL1b1) enhanced the efficiency and kinetics of iPSC 
reprogramming and also the quality of the resultant iPSCs. TCL1 and TCL1b1 are known 
to bind to and potentiate the activity of the AKT1 signaling kinase, and accordingly, 
overexpression of AKT1 also enhanced iPSC cell reprogramming efficiency. This 
implicated for the first time a direct requirement for PI3K/AKT1 signaling in iPSC 
reprogramming. However, despite being well known for binding to AKT1 as a cofactor, 
TCL1 appeared to act in a mechanism that was partially independent of AKT1 as 
opposed to TCL1b1. PNPase is another newly identified binding partner of TCL1 and 
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was shown in the present study to be a downstream AKT1-independent target of TCL1. 
PnPase plays a role in maintaining mitochondrial homeostasis and ROS production and 
thus it is an interesting target to study with the hope that downregulation of PNPase 
would enhance the metabolic and nuclear reprogramming.  
Since TCL1 and TCL1b1, which are highly enriched in oocytes, are shown in the 
present study to augment the iPSC generation by activating multiple pro-reprogramming 
pathways. Therefore, TCL1 and TCL1b1 might serve as a link between somatic nuclear 







TCL1  T-cell leukemia 1 
TCL1b1  T-cell leukemia 1b1 
AKT1  V-akt murine thymoma viral oncogene homolog 1 
PI3K  Phosphatidylinositol 3-kinases 
PnPase  Polynucleotide Phosphorylase 
Oct4  Octamer-binding transcription factor 4 
Sox2  SRY (sex determining region Y)-box 2  
Klf4  Krueppel-like factor 4  
cMyc    Myelocytomatosis cellular oncogene homolog 
Rex1/Zfp-42 Zinc finger protein 42 homolog 
Nanog  Nanog homeobox 
Gtl-2/Meg3 Maternally expressed 3  
Rian  RNA imprinted and accumulated in nucleus 
Tbx3   T-box transcription factor 3 
ESCs  Embryonic Stem cells 
iPSs  Induced pluripotent stem cells 
SCNT  Somatic cell nuclear transfer 
OSK  Oct4, Sox2 and Klf4 
OSKC  Oct4, Sox2, Klf4 and cMyc 
Oct4-GFP Green fluorescence protein tagged Oct4 protein 
SSEA-1 Stage-specific embryonic antigen 1 
MET  Mesenchymal-to-epithelial transition  
EMT  Epithelial-to-mesenchymal transition 
Dox   Doxycycline    
shRNAs Small hairpin RNA 
EV  Empty vector 
ROS  Reactive oxygen species 
MEFs  Mouse embryonic fibroblasts 
KD  Knock down 
TMRM Etramethylrhodamine methyl ester  
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CHAPTER 1: INTRODUCTION 
1.1  Pluripotent stem cells and their implication in developmental biology 
In mammalian development, unidirectional process occurs from the totipotent 
zygote to pluripotent inner cell mass (ICM) and epiblast cells, from which more restricted 
and eventually differentiated cells are derived.  
Stem cells are characterized by their ability to both self-renew and to generate 
differentiated functional cell types. Pluripotent embryonic stem cells (ESCs) are derived 
from the embryo while unipotent/multipotent adult stem cell can be found in various 
sources of the postnatal animal. The first isolation of mouse ESCs enabled introduction of 
targeted genetic modification into the germ line through homologous recombination and 
thus facilitated gene function analysis (Evans & Kaufman, 1981; Gossler et al, 1986; 
Robertson et al, 1986; Thomas & Capecchi, 1986; Thomas et al, 1986). Mouse ESCs are 
extremely efficient in germline contribution and moreover, able to form an entire adult 
upon injection into tetraploid blastocysts, which commit only to extra-embryonic 
membranes and placenta (Nagy et al, 1993).  
Following the first attempt to manipulate differentiation of mouse embryonic 
carcinoma cells with chemicals (McBurney et al, 1982), stem cell research started to 
focus on understanding the mechanisms for maintenance of the pluripotent state and the 
pathways leading to lineage specification. Earlier studies have shed lights on the genetic 
control of pluripotency and self-renewal of ESCs (i.e. Oct4, Sox2 and Nanog), and how 
these core regulators collaborate with other factors to form the basis of a transcription 
factor circuitry in maintaining pluripotency and lineage specification of ESCs (Avilion et 
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al, 2003; Boyer et al, 2006; Chambers et al, 2003; Chambers et al, 2007; Nichols et al, 
1998; Niwa et al, 2000).  In addition, various signaling pathways have also been shown 
to converge to the core transcriptional regulatory network in maintaining the stem cell 
state (Boiani & Scholer, 2005). The successful isolation and culture of human ESCs 
(Thomson et al, 1998) represented the first big step towards realization of the application 
of stem cells in regenerative medicine. (Thomson et al, 1998). With these knowledge and 
materials, it is now possible to direct differentiation of ESCs along pre-determined 
pathways by manipulating the regulatory circuitry with combinations of chemicals, 
growth factors and matrices (Wobus & Boheler, 2005). The directed differentiation of 
ESCs into specific lineages not only enables cell-based or tissue-based therapy but also 
development of disease models to study the mechanisms of pathogenesis.  
1.2  Nuclear reprogramming in somatic cells 
The paramount importance of the generation of differentiated derivatives of 
human ESCs which are genetically identical to the recipients has motivated researchers to 
find ways to generate human stem cells that can be cultured indefinitely to produce 
sufficient source for cell replacement therapy. Isolation of adult stem cells from sources 
like bone marrow, adipose, skin and umbilical cord blood, is easier and natural and has 
been used to treat a vast variety of diseases and disorders (Harris et al, 2007). However, 
the availability of such stem cells is limited and majority of these cells cannot be cultured 
indefinitely. For instance, stem cells from tissues such as liver, adipose and muscles, 
possess limited ability to expand and isolation of adult stem cells is not possible if the 
tissue of origin is diseased or aged. Although cord blood is one of the most readily 
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available stem cells sources, autologous therapy is only possible if it is collected and 
maintained properly since born.  
While it has been conventionally held hat embryonic development is 
unidirectional and the lineage specification is irreversible, some studies have implied that 
‘committed’ cells are plastic as the fate of these cells can switch when they are explanted 
and expose to a different microenvironments (Gehring, 1967; Hadorn, 1966; Le Lièvre & 
Le Douarin, 1975). The plasticity of specialized cells was proven valid by conclusive 
evidence from elegant cloning studies in frogs whereby the transfer of nuclei from early 
blastocysts into enucleated oocytes resulted in clones of swimming tadpoles (Briggs & 
King, 1952; Gurdon, 1962a; Gurdon, 1962b). This technique is known as somatic cell 
nuclear transfer where a nucleus from a differentiated somatic cell is transplanted into an 
enucleated oocyte for initiation of nuclear reprogramming and leads to the generation of 
an entire individual, which is a genetically identical clone of the original somatic cell. 
This has invalidated the ‘unidirectional and irreversible’ developmental concept by 
showing that despite being stably silenced in specialized cells, all the genes required for 
directing the development of an organism, can be re-activated and the process of 
differentiation can be fully reversed.  
Decades later, successful SCNT was carried out in mammals, first cloning of 
‘Dolly the sheep’ followed by SCNT in mouse and other species (Kawase et al, 2000; 
Munsie et al, 2000; Thuan et al, 2010; Wakayama et al, 2001; Wilmut et al, 1997). More 
importantly, reprogramming with SCNT was also proven successful with terminally 
differentiated cells, e.g. olfactory neurons or B cells, suggesting that nuclear 
reprogramming does occurs and it is not due to the presence of contaminating stem cells 
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or progenitor cells (Eggan et al, 2004; Hochedlinger & Jaenisch, 2002; Li et al, 2004). 
This has provided a definitive proof that pluripotency can be restored to the nucleus of a 
terminally differentiated cell. Successful SCNT in mammals has unleashed the invaluable 
potential of therapeutic and reproductive cloning for application in regenerative medicine 
and agriculture. Despite extensive studies on human SCNT (Hall et al, 2007; Lavoir et al, 
2005; Stojkovic et al, 2005), to date, no human SCNT-derived ESC line has been 
successfully derived except for a recent study in which a triploid pluripotent stem cells 
containing a diploid genome complement of the somatic cell and a haploid genome 
complement of the oocyte were generated (Noggle et al, 2011). Nevertheless, non-human 
primate therapeutic cloning has been performed successfully with SCNT and could serve 
as an alternative resource for human study (Byrne et al, 2007).  
SCNT is conceptually straightforward, but technically demanding. Furthermore, 
progress in human SCNT has been marred by technical difficulties and controversy. First, 
it requires a substantial supply of oocytes which raises fundamental ethical concerns 
surrounding its potential application to human cells as fresh oocytes must be obtained 
from a healthy female donor. Attempts have been made to minimize such concerns. For 
example, SCNT with aged oocytes from failed in vitro fertilization attempts, which are a 
more accessible and abundant source, has been proven successful albeit with low 
efficiency (Hall et al, 2007; Wakayama et al, 2007). Second, the destruction of human 
blastocysts, which is inevitable in the procedure, has engendered strong opposition in 
many countries because of moral and religious issues. These controversies have raised 
serious concerns about the suitability of this technique for the future production of 
patient-matched ESCs for therapeutic cloning, and these are major practical problems that 
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could hamper the eventual application of nuclear transplantation for regenerative 
medicine. 
During this period of time, research and development in other nuclear 
reprogramming techniques have been on-going concurrently. For instance, cell fusion 
assay that involves fusion of two or more cell types to form a single entity. This 
technique has been used to study the impact of one genome on another and allows for 
discovery of trans-acting repressors and tumour-suppressor proteins (Davidson et al, 
1966; Harris et al, 1969; Sparkes & Weiss, 1973). About a decade later, cell fusion 
studies provided complimentary evidence for the first time that the differentiated state of 
mammalian somatic cells is not irreversibly fixed, but, is dictated instead, by the balance 
of regulatory proteins (Blau et al, 1985; Blau et al, 1983; Miller & Ruddle, 1976; Miller 
& Ruddle, 1977). Pluripotent cell types such as embryonic carcinoma cells (ECCs), 
embryonic germ cells (EGCs), and ESCs, have all been shown to restore pluripotent 
properties when they are fused to various somatic cells. Thus, this suggests that these 
cells may possess reprogramming components similar to those found in oocytes (Blau et 
al, 1983; Flasza et al, 2003; Forejt et al, 1984; Matveeva et al, 1998; Miller & Ruddle, 
1976; Miller & Ruddle, 1977; Tada et al, 1997b; Tada et al, 2001a). Human ES cells have 
also been proven useful for cell fusion assays and ave the potential to reprogram somatic 
nuclei after fusion (Cowan et al, 2005; Yu et al, 2006). 
The nature of cell fusion assays where heterokaryons are formed rapidly makes it 
a useful tool for elucidating the molecular mechanisms that are required for initiating 
reprogramming to a pluripotent state. For instance, through loss-of-function and gain-of-
function approaches, Oct4 was shown to be required for reprogramming towards 
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pluripotency when mouse ESCs that had lost Oct4 expression failed to reprogram human 
B cells upon cell fusion (Pereira et al, 2008). Researchers have also uncovered, with cell 
fusion assay, that active DNA methylation is essential for induction of nuclear 
reprogramming of fibroblasts toward pluripotency (Bhutani et al, 2010b). Despite being 
an excellent model for study of reprogramming mechanisms, tetraploidy of the 
reprogrammed cells presents a major shortcoming for using such an approach for 
customized cell therapy. Diploid reprogrammed cells are difficult to derive with cell 
fusion technique due to the risk of generating large-scale genomic instability although 
selective elimination of some ESC-derived chromosomes is possible (Matsumura et al, 
2007). 
Instead of technically demanding SCNT and non-clinically relevant cell fusion 
assays, short-term incubation of permeabilized somatic cells with extracts of oocytes and 
ESCs was claimed to result in genome-wide reprogramming (Alberio et al, 2005; Bian et 
al, 2009; Taranger et al, 2005). This technique helps to identify and understand the 
effects of soluble factors in the extracts on the somatic nucleus. However, convincing 
evidence for reprogramming of the somatic cell genome in such culture-induced 
reprogramming is still lacking.  
All these techniques demonstrated the biological reality of nuclear 
reprogramming in which the genomic modifications that are imposed on cells during 
differentiation and development are reversible. However, the nature and identity of the 
factors in an oocyte or pluripotent cells that drive the reprogramming activities have 
remained elusive. This has prompted scientists to hunt for molecular factors present in 
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these cells that might drive reprogramming with the perception that the nuclear 
reprogramming process is highly complex and might entail a large repertoire of proteins. 
In the year 2006, Takahashi and Yamanaka successfully achieved in vitro direct 
isolation of pluripotent ESC–like cells from cultured somatic fibroblasts and this has 
created a milestone in nuclear reprogramming history. In this method, murine somatic 
fibroblasts were reprogrammed into induced pluripotent stem cells (iPSCs), which are 
capable of forming chimeras and germ line transmission, by overexpression of defined 
transcription factors (Okita et al, 2007; Takahashi & Yamanaka, 2006).  Leveraging the 
knowledge that ES cells harbour reprogramming activities, the authors reasoned that 
forced overexpression of ES cell-specific genes, particularly transcription factors, in 
somatic cells might induce them to adopt an embryonic-like program. An elegantly 
designed experiment was carried out in which a panel of 24 genes previously implicated 
in self-renewal and pluripotency of ES cells were tested and subsequently narrowed down 
to a pool of four transcription factors: Oct4 (also known as Pou5f1), Sox2, Krüppel-like 
factor 4 (Klf4) and cMyc (Takahashi & Yamanaka, 2006). Nowadays, iPSC 
reprogramming can be applied to a plethora of differentiated human cells in a clinically 
relevant manner (Kaji et al, 2009; Kim et al, 2009; Warren et al, 2010; Woltjen et al, 
2009; Yamanaka, 2009).  
Not only does the work of Takahashi and Yamanaka lend important insight into 
the molecular mechanism of reprogramming and pluripotency, it also represents a 
significant step toward a rational approach for generating patient-specific ESC lines that 
can be used for autologous cell replacement therapy and establishment of disease models 
(Dimos et al, 2008; Ebert et al, 2009). This is because skin fibroblasts can be readily 
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sampled from a patient, induced to become pluripotent in vitro and subsequently undergo 
directed differentiation to generate cell types of interest which are difficult to obtain (e.g 
cardiac, lung and neuronal cells). Previously inaccessible cell types can hence be 
produced on a large scale through this method. Moreover, disease pathogenesis and 
signalling pathways can be studied in those inaccessible cell types and drug screening can 
be carried out in vitro using these models to test for drug candidates (Figure 1). For 
instance, the successful differentiation of patient specific iPSCs into motor neurons 
demonstrated the feasibility of applying these cells in regenerative medicine and in vitro 
modelling of motor neuron diseases (Karumbayaram et al, 2009). Hence, the process of 
iPSC cell generation is not only provocative in that it entails the creation of unrestricted 
pluripotent states from lineage-restricted differentiated cells, but it also promises 
therapeutic and translational breakthroughs in the near future. Furthermore, this method 
is hindered by neither the logistical constraints (i.e. oocyte donors) nor the ethical 







Illustration 1 | Comparison between different nuclear reprogramming methods.  
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Schematic diagram showing the comparison between cell fusion, SCNT and iPSC 
reprogramming methods based on mechanistic insights and therapeutic applications. 
(Adapted from Yamanaka and Hellen, Nature, 2010) 
 
1.3  Efforts on improving efficiency and clinical relevance of iPSCs  
Although iPSC reprogramming appears to be the simplest, most ethical and 
clinically sound among all nuclear reprogramming techniques, it is the slowest and most 
inefficient reprogramming process (Illustration 1). Efforts have been directed towards 
improving the kinetic and efficiency of iPSC reprogramming process.  
With the knowledge learnt from previous studies on SCNT, researchers have 
shown that, similar to SCNT, addition of small molecules targeting chromatin 
modification (e.g. histone deacetylation and methylation) resulted in a modest increase in 
reprogramming efficiency (Huangfu et al, 2008a). Furthermore, fibroblasts could regain 
pluripotency by overexpression of fewer reprogramming factors without oncogenic Klf4 
and cMyc (Huangfu et al, 2008b). 
In addition to chromatin modification, reprogramming efficiency could also be 
improved by modulating cellular signalling pathways. For instance, dual inhibition of 
MEK-ERK pathway and TGFβ signalling could promote cell cycle progression 
specifically in somatic cells and favor mesenchymal to epithelial transition which are 
some of the critical steps in iPSC reprogramming (Lin et al, 2009).  On the other hand, 
glycogen synthase kinase 3 (GSK-3) inhibitor could be used to replace Sox2 and another 
group found a small molecules cocktail that enabled the generation of iPSCs with Oct4 
alone (Li et al, 2009b; Zhu et al, 2010). This is a big step towards the goal of 
reprogramming with only small molecules, which is a safer option for genetic modulation. 
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Modulation of extrinsic signaling through exposure to hypoxic environment or ascorbic 
acid has been shown to increase the frequency of iPSC formation (Esteban et al, 2010; 
Yoshida et al, 2009). 
Reprogramming could also become more efficient when the signalling pathways 
mediated by the tumour-suppressor protein p53 or the cell-cycle regulator INK4A are 
disrupted (Kawamura et al, 2009; Li et al, 2009a; Marion et al, 2009; Utikal et al, 2009). 
In addition, certain microRNAs have also been described to enhance the efficiency of 
reprogramming (Judson et al, 2009).  
Patient specific-iPSCs have great potential for therapeutic application as they can 
now be derived without viral or transgenic integrations that may modify the host genome. 
For instance, alternative reprogramming factor delivery methods such as repeated 
transfection of plasmids, nucleofection of modified mRNA and incubation with 
membrane permeable recombinant reprogramming proteins, have been shown to generate 
virus free iPSCs that are clinically relevant (Kim et al, 2009; Lee et al, 2011; Okita et al, 
2008; Warren et al, 2010; Zhou et al, 2009). Earlier research indicated high similarities 
between ESCs and iPSCs. These included indistinguishable global histone modification 
and DNA methylation patterns (Maherali et al, 2008; Mikkelsen et al, 2008). 
Furthermore, iPSCs, like ESCs, gave rise to various differentiated cell types including 
germ cells, as shown in the context of chimeric animals and support the development of 
all-iPSC mice using tetraploid complementation, the most stringent assay for 
development (Boland et al, 2009; Kang et al, 2009; Okita et al, 2007; Zhao et al, 2009).   
Despite these similarities, there is emerging evidence for substantial differences in 
developmental potentials between ES cells and iPSCs. For instance, unlike ESCs, most 
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iPSC clones give rise to low-grade chimeras after injection into diploid blastocysts and 
are not capable of tetraploid complementation (Hanna et al, 2008; Kim et al, 2008b; 
Meissner et al, 2007; Stadtfeld et al, 2010a). At the molecular level, several reports 
demonstrated major differences between ESCs and iPSCs in terms of mRNA and 
microRNA expression levels, as well as in DNA methylation patterns that may affect the 
differentiation potential of iPSCs (Chin et al, 2009; Doi et al, 2009; Marchetto et al, 2009; 
Pick et al, 2009; Stadtfeld et al, 2010a; Wilson et al, 2009). Recently, intergenic non-
coding RNAs (lincRNAs) were shown to be differentially expressed between human 
iPSCs and ESCs, and a few of these lincRNAs in fact play important roles in the 
reprogramming process (Loewer et al, 2010). These findings suggest that somatic iPSC 
reprogramming may result in cellular abnormalities which could impede their therapeutic 
utility. 
The potential of iPSC reprogramming is remarkable, but this technology is still in 
its infancy. To realize the full application of iPSC cells, it is critical to continue to 
improve the methodologies for iPSC derivation and to precisely evaluate each clone and 
subclone of iPSCs for their safety and efficacy. In addition, molecular mechanisms in the 
reprogramming process should be fully explored in order to have a precise modulation of 
different pathways or transcriptional regulatory networks that aid in achieving the full 
potential of iPSC in regenerative medicine. 
1.4  Mechanistic insights in iPSC reprogramming 
Many methods have been developed to introduce the reprogramming factors into 
somatic cells, but so far only a small percentage of cells expressing the factors were 
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successful in becoming completely reprogrammed to gain pluripotency. For instance, 
even when most of the cells are induced to express all the reprogramming factors using 
polycistronic cassettes in a single vector, or by using a secondary inducible 
reprogramming platform, the proportion of faithfully reprogrammed colonies still 
remains low (Carey et al, 2008; Chang et al, 2009; Gonzalez et al, 2009; Hockemeyer et 
al, 2008; Maherali et al, 2008; Shao et al, 2009; Sommer et al, 2009; Stadtfeld et al, 
2010b; Wernig et al, 2008a). An earlier hypothesis that only progenitor or adult stem 
cells are amenable for reprogramming has been disapproved as one of the explanations 
for the low efficiency when it was shown that terminally differentiated cells, such as 
pancreatic islet or terminal blood lineages, could give rise to iPSCs (Aoi et al, 2008; 
Eminli et al, 2009; Hanna et al, 2008; Hanna et al, 2009; Loh et al, 2009; Loh et al, 2010; 
Seki et al, 2010; Stadtfeld et al, 2008a). However, it is still unclear whether the degree of 
differentiation of somatic cells would affect the efficiency and kinetics of reprogramming 
(Eminli et al, 2009; Hanna et al, 2009; Shi et al, 2008). Other suggested explanations for 
low reprogramming efficiency included heterogeneous transgene expression across the 
starting cell population that were infected with individual viral vectors and insertional 
mutagenesis upon viral infection of the reprogramming transgenes. However, all these 
have been discredited since efficiency remained low when these proposed issues were 
solved by using polycistronic vectors and secondary reprogramming system as mentioned 
above. All these findings have led to a hypothesis that reprogramming is a stochastic 
event and overexpression of the reprogramming factors per se is not sufficient for faithful 
nuclear reprogramming, and additional events or mechanisms are required to overcome 
major epigenetic barriers that prevent reprogramming (Hanna et al, 2009; Smith et al, 
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2010). Therefore, extensive research studies are critical in order to gain further 
mechanistic insights in iPSC reprogramming before any strategies could be proposed.  
Two of the key mechanistic processes that need to be understood are erasure of the 
somatic program and the establishment of an ESC-like transcription network that confer 
pluripotency capabilities.   
Capturing reprogramming events that occur at different phases of reprogramming 
has been challenging as fewer and fewer cells are transited towards the pluripotent state 
because of the persistent low efficiency and slow kinetics of reprogramming despite all 
the modifications made in the protein delivery methods as mentioned earlier. Initial 
studies used MEFs with a genetically modified reporter system (i.e. Oct4-GFP or Nanog 
GFP) that allowed for easy identification of reprogrammed cells. In combination with 
immunostaining using early markers of reprogramming such as stage-specific embryonic 
antigen 1 (SSEA-1), reprogramming of MEFs with such reporters allow isolation of 
partial reprogrammed iPSCs (pre-iPSCs)  that serve as a useful platform to study the 
molecular mechanisms during the early and late phase of iPSC reprogramming 
(Mikkelsen et al, 2008; Silva et al, 2008; Sridharan et al, 2009). In addition, there has 
been tremendous development of technologies, for instance, reprogramming system like 
Doxycycline-inducible secondary expression system and live imaging analysis, that has 
accelerated the understanding of mechanistic insights in iPSC reprogramming. 
1.4.1 The steps in iPSC reprogramming 
In general, successful iPSC reprogramming in mouse involves stepwise transition 
through intermediate steps at which fewer and fewer cells are able to progress owing to 
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lack of important secondary events. During the early phase, proliferation is induced and 
somatic cell specific transcription is down regulated. This is followed by acquisition of 
epithelial characteristics and activation of some ESC markers, for example, alkaline 
phosphatase and SSEA-1. At the late stage of reprogramming, endogenous pluripotency 
genes, for instance, Nanog and Oct4, are activated. During the early- and mid-phase of 
the reprogramming process, the acquisition of an iPSC state requires continuous 
expression of the reprogramming factors. At the end of the process, stable conversion of 
cell fate is achieved, and the maintenance of iPSCs becomes independent of their 
overexpression (Brambrink et al, 2008; Koche et al, 2011; Li et al, 2010; Samavarchi-
Tehrani et al, 2010; Silva et al, 2008; Smith et al, 2010; Sridharan et al, 2009; Stadtfeld 
et al, 2008b). 
Studies have suggested that the termination of the somatic program is a lower 
barrier to reprogramming than the acquisition of the ESC program as only a minute 
population of cells underwent transitional change to form pluripotent cells despite the fact 
that the majority of them showed down-regulation of somatic markers (Stadtfeld et al, 
2008b). In addition, the induction of the pluripotent state may only be possible after the 
master regulators of the somatic state are completely silenced since the overexpression of 
lineage-specific transcription factors dominantly suppressed reprogramming in somatic 
cells (Hawkins et al, 2010; Mikkelsen et al, 2008). The silencing is often associated with 
a change in chromatin structure at the enhancers and promoters, and in particular with a 
loss of histone H3K4me2 (Koche et al, 2011). Phenotypically, mesenchymal cells like 
fibroblasts underwent a mesenchymal-to-epithelial transition (MET) as opposed to 
epithelial-to-mesenchymal transition (EMT) that occur during the differentiation of 
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fibroblasts in vivo. The role of MET in reprogramming has been supported by the 
findings that modulating signaling pathways, for example, anti-MET transforming 
growth factor-β (TGFβ) and pro-MET bone morphogenetic protein (BMP), would 
significantly affect reprogramming efficiency (Li et al, 2010; Samavarchi-Tehrani et al, 
2010). Changes in chromatin modification at the pluripotency-related genes also occur at 
this stage although transcriptional upregulation occurs much later (Koche et al, 2011). 
After epithelial features have been established, other ESC markers such as SSEA-
1 and many embryonic genes were expressed by a subset of epithelial-like cells 
(Brambrink et al, 2008; Li et al, 2010; Mikkelsen et al, 2008; Samavarchi-Tehrani et al, 
2010; Sridharan et al, 2009; Stadtfeld et al, 2008b). As with earlier steps, only a small 
population of SSEA-1 positive cells progressed to the last step of reprogramming at 
which they gave rise to faithfully reprogrammed cells and activated the expression of the 
pluripotency network (Brambrink et al, 2008; Stadtfeld et al, 2008b).  
1.4.2 The roles of reprogramming factors in iPSC reprogramming   
To understand the molecular mechanisms underlying the induction of 
pluripotency, first, it is important to learn the contribution of each reprogramming factor 
to the different steps of reprogramming. For instance, studies revealed that each of the 
reprogramming factors targets distinct modulators of MET, suggesting that they have a 
distinct role in the process (Li et al, 2010; Markoulaki et al, 2009; Nakagawa et al, 2008; 
Sridharan et al, 2009). For instance, Oct4 and Sox2 cooperate to suppress the pro-
mesenchymal regulator Snail while Klf4 induces the epithelial program by directly 
binding to and activating epithelial genes, including E-cadherin. On the other hand, Myc 
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antagonizes TGFβ signaling  that is anti-MET by repressing Tgfb1 and Tgfbr1 (Li et al, 
2010). The collaborative actions of the canonical Yamanaka reprogramming factors on 
the induction of MET transition explain how this simple reprogramming cocktail could 
initiate efficient direct reprogramming.  
During the last phase of reprogramming, the pluripotency network is established. 
Genome-wide binding site mapping studies in iPSCs and pre-iPSCs show that the binding 
patterns of Oct4, Sox2, Klf4, and cMyc are similar to that in ESCs. For instance, during 
reprogramming, Oct4 and Sox2 co-occupy promoters of several genes that are highly 
expressed in ESCs. On the other hand, Klf4 shares roughly half of its targets with Oct4 
and Sox2 (Chen et al, 2008; Kim et al, 2008a; Loh et al, 2006; Sridharan et al, 2009).  
Notably, cMyc differs functionally from Oct4, Sox2 and Klf4 in that it targets 
predominantly the regulators of cellular proliferation, biosynthetic and metabolic 
pathways whereas Oct4, Sox2 and Klf4 target mainly the mediators of pluripotency 
network and development (Chen et al, 2008; Jiang et al, 2008; Kim et al, 2008a; Loh et 
al, 2006; Sridharan et al, 2009). Therefore, cMyc does not take part in the final stage of 
reprogramming and instead it might lay the foundation for the other reprogramming 
factors to activate the pluripotency network. This notion is further supported by the 
chromatin binding mapping of the four transcription factors in which cMyc binding at its 
targets was largely established in the pre-iPSCs whereas the bindings of the other three 
factors at pluripotency-related genes were undetectable in pre-iPSCs (Kim et al, 2010a; 
Sridharan et al, 2009).  Therefore, it has been proposed that during the final step of 
reprogramming, the binding of Oct4, Sox2 and Klf4 to their target pluripotency genes 
and subsequent transcriptional upregulation represent a major barrier to the 
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accomplishment of reprogramming (Sridharan et al, 2009).  This might be explained by 
either the lack of additional transcription factors that are required for cooperative binding 
with the reprogramming factors at the intermediate stage of reprogramming or the 
formation of repressive chromatin at the pluripotency gene promoters and enhancers that 
interferes with binding of the reprogramming factors (Feldman et al, 2006; Sridharan et 
al, 2009; Theunissen et al, 2011). A recent study elegantly supports these two models by 
showing that overexpression of Nanog, a transcription factor that interacts with and co-
occupies many target genes with Oct4 and Sox2 synergistically enhanced the final phase 
of reprogramming when DNA methylation is inhibited (Theunissen et al, 2011).  
A recent study showed that iPSC reprogramming is possible with distinctive 
reprogramming cocktail of transcription factors albeit with lower efficiency, for instance, 
a combination of Lin28, Sall4, Esrrb, and Dppa2 (Buganim et al, 2012). It has been 
shown that Sall4 can activate the distal enhancer of Oct4 and Esrrb can upregulate Sox2 
and other pluripotency genes (Feng et al, 2009; Zhang et al, 2006a). On the other hand, 
Lin28 regulates the expression of Oct4 at post-transcriptional level in ESCs and has been 
shown to be able to reprogramming human fibroblasts to iPSCs with Oct4, Sox2 and 
Nanog (Qiu et al, 2010; Yu et al, 2007). In addition, the expression of Esrrb, Utf1, Lin28, 
and Dppa2 are better early predictors for fully reprogrammed iPSCs than expression of 
the previously suggested reprogramming markers Fbxo15, Fgf4, and Oct4 (Brambrink et 
al, 2008; Buganim et al, 2012; Takahashi & Yamanaka, 2006). The mechanisms 
underlying the initiation of reprogramming by these newly identified reprogramming 
factors warrants further investigation.  
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1.4.3 The chromatin states in iPSC reprogramming   
Epigenetic reprogramming, that encompasses a broad range of chromatin 
modifications, such as DNA methylation, histone modifications, nucleosome 
organization and higher order chromatin structure organization,  is another important 
hurdle that somatic cells need to overcome in order to achieve pluripotency faithfully. 
This is based on the observation that the genome of somatic cells is predominantly in a 
heterochromatic conformation whereas for stem cells, their genome is mostly in a 
euchromatic conformation. Therefore, epigenetic reprogramming is required to reset the 
somatic genome to pluripotency-like chromatin structure. However, in factor-mediated 
iPSC reprogramming, this epigenetic hurdle is now believed to be one of the major 
roadblocks that cause inefficiency of reprogramming (Hanna et al, 2009; Smith et al, 
2010). During the derivation of iPSCs, DNA demethylation in iPSC reprogramming takes 
from days to weeks to complete (Mikkelsen et al, 2008; Santos et al, 2002). Previous 
study showed that, epigenetic memory of the somatic DNA methylation pattern is often 
retained in mouse iPSC cells which would influence subsequent directed differentiation 
for application in disease modelling or treatment (Kim et al, 2010b; Polo et al, 2010). 
Such epigenetic memories have also been observed in human iPSCs and hence may shed 
light on processes that are difficult to reset during reprogramming (Doi et al, 2009; 
Marchetto et al, 2009). In another study, aberrant DNA hypermethylation and 
hypoacetylation has led to silencing of Dlk1-Dio3 gene locus that has been associated 
with developmental potential of stem cells (Stadtfeld et al, 2010a). These observations 
could be explained by the inefficient demethylation that occurs stochastically and 
passively in iPSC factor-based reprogramming. Such demethylation not only fails to 
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properly erase parts of the somatic DNA methylome, which leads to an epigenetic 
memory, it may also induce aberrant methylation that appears to be iPSC specific, and 
prevents the re-establishment of ESC-like methylation (Lister et al, 2011; Mikkelsen et al, 
2008; Santos et al, 2002).  
Presently, findings on the functional and molecular distinctions between iPSCs 
and ESCs have firmly indicated that the reprogramming process involves a wide variety 
of molecular changes, giving rise to cells that are either partially reprogrammed, or 
reprogrammed with retention of epigenetic memory or bona fide iPSCs. Despite the 
tremendous efforts that have been made to augment the iPSC reprogramming process, the 
kinetics, efficiency and pluripotency potential of iPSCs remain relatively poor. This 
suggests that there are other unexplored barriers to the reprogramming process that exist 
beyond expression of the four reprogramming factors. Therefore, it is essential to extend 
our understanding on the molecular steps underpinning iPSC reprogramming that would 
not only pave the way for developing strategies to improve the current reprogramming 
regime, but will also provide effective means to evaluate the therapeutic safety and 
validity of iPSCs. 
1.5  The potential of oocyte factors as powerful players in iPSC reprogramming 
SCNT is able to efficiently (30-50%) generate nuclear transfer-derived ESCs (nt-
ESCs) that are capable of development to the blastocyst stage (Kruip & den Daas, 1997; 
Nakamura et al, 2008). Moreover, nuclear transfer also generates cells that are more 
completely reprogrammed than iPSCs since, regardless of donor cell identity, nt-ESCs 
are molecularly and functionaly indistinguishable from ES cells derived from fertilized 
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embryos (Brambrink et al, 2006; Eggan et al, 2004; Hochedlinger & Jaenisch, 2002; Li et 
al, 2004; Wakayama et al, 2006). Unlike the slow and passive demethylation in iPSC 
reprogramming, demethylation in SCNT commences immediately upon transfer of a 
somatic nucleus into ooplasm and occurs in an active manner (Mikkelsen et al, 2008; 
Santos et al, 2002). This suggests that nuclear transfer is more effective at establishing 
the ground state of pluripotency than iPSC reprogramming. Previous studies that havw 
directly compared the developmental potential of iPSCs and nt-ESCs showed that all nt-
ESC clones displayed ESC-like developmental potential and are capable of contributing 
to viable all-iPSC mice whereas only less than 5% of iPSC clones exhibited full 
developmental potential (Kim et al, 2010b; Polo et al, 2010; Stadtfeld et al, 2010a).  
All these observations appear to suggest that there are powerful reprogramming 
factors present in the oocyte and many of them could be important players in iPSC 
reprogramming that may act synergistically with Yamanaka’s reprogramming factors. In 
fact, the important role of oocyte factors in iPSC reprogramming is strongly supported by 
a recent study in which they showed that an oocyte-specific transcription factor, Glis-1, 
significantly improved the iPSC reprogramming efficiency in both human and mouse 
fibroblasts by activating multiple pro-reprogramming pathways (Maekawa et al, 2011). 
In addition, it has been shown that Glis-1 interacted physically with OSK, suggesting that 
this oocyte-specific transcription factor is required for cooperative gene up-regulation 
with the Yamanaka reprogramming factors. Therefore, the effect of Glis-1 on iPSC 
reprogramming is the first direct evidence showing the potential link between 
reprogramming during iPSC derivation and reprogramming after nuclear transfer.  
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Oocytes have the unique natural ability to remodel the chromatin of the germinal 
nuclei into a totipotent state and to demethylate a transferred somatic nucleus (Fulka et al, 
2004; Mayer et al, 2000). In fact, a few oocyte factors have been implicated in such 
enzyme-catalyzed active demethylation during mammalian development and nuclear 
reprogramming.  These factors are namely, methyl binding domain protein binding 4 
(MBD4), activation-induced cytidine deaminase (AID), and growth arrest and DNA 
damage-inducible protein alpha (Gadd45a). This enzymatic complex causes cytosine 
deamination and base excision repair which would lead to DNA demethylation without 
replication. In addition, the authors have demonstrated that AID-dependent DNA 
demethylation is an early epigenetic event necessary for the re-establishment of 
pluripotency state in human fibroblasts during SCNT (Bhutani et al, 2010b).  
Another possible role of oocyte factors is to establish the pluripotency state in the 
embryo or of somatic cells. For instance, Oct4, one of the Yamanaka’s reprogramming 
factors and also the core pluripotency regulators, is present in the oocyte and is expressed 
throughout the pre-implantation period (Okamoto et al, 1990; Rosner et al, 1990; Scholer 
et al, 1989; Scholer et al, 1990). Tumor translationally controlled protein 1 (Tpt1) is 
another oocyte factor which has been shown to activate Oct4 and Nanog expression 
during SCNT and therefore play a role in the initiation of the pluripotency state of the 
somatic nucleus (Koziol et al, 2007). Oocyte factor Ronin was also found to be involved 
in pluripotency gene regulation network through epigenetic regulation or control of RNA 
stability (Dejosez et al, 2008).  
Although it has been implicated that oocyte factors may enhance the generation of 
induced pluripotent stem cells (Assou et al, 2009; Gurdon & Melton, 2008; Zhang et al, 
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2009a), the reprogramming factors in oocytes remains undetermined. This is partly due to 
the fact that the protein composition of oocytes remained mostly unidentified (Wang et al, 
2010b).  Studies in oocytes of some species have pointed out some potential 
reprogramming proteins (Hansis et al, 2004; Kikyo et al, 2000; Koziol et al, 2007; Tani 
et al, 2007) but these findings await confirmation in mammalian oocytes.  
In addition to oocytes, fertilized eggs (or zygotes) may also be used to execute 
successful SCNT  since maternal reprogramming factors are still present at the zygotic 
stage of embryonic development (Egli et al, 2007). Notably, nuclear material from 
somatic cells is not removed as an intact nucleus during SCNT. In fact, only the complex 
of the condensed chromosomes and the spindle are carefully extracted at cell cycle 
phases at which the nuclear envelope has broken down during meiosis in oocytes or at 
metaphase in zygotes undergoing mitosis (Yamanaka & Blau, 2010). During nuclear 
envelope breakdown, nuclear proteins are released into the ooplasm. Therefore, 
reprogramming factors can be present in the nucleus or cytosol of the oocyte. In addition, 
nuclear reprogramming by oocytes takes place without cell division and does not require 
protein synthesis (Gurdon & Melton, 2008). This suggests that oocyte reprogramming 
proteins should be present in high abundance to allow for effective exchange with 
proteins in implanted somatic nuclei so that nuclear reprogramming can be completed 
(Gurdon, 2009). In cell fusion experiments, fusion with embryonic stem (ES) cells 
induces somatic cells to become reprogrammed into pluripotent stem cells (Tada et al, 
2001b). This implies that oocyte reprogramming factors are also likely to be factors that 
are also expressed in ES cells. However, this implication has been challenged by other 
observations whereby expression signatures shared by oocyte and ES cells do not cover 
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pluripotency core transcriptional genes, for instance, Sox2 and Nanog (Assou et al, 2009). 
In addition, oocyte neither expresses Klf4 nor cMyc, the two important factors of the 
Yamanaka’s iPSC reprogramming cocktails but all four factors are expressed in ES cells 
(Assou et al, 2009; Takahashi et al, 2007; Takahashi & Yamanaka, 2006). Since erasure 
of the donor cell epigenetic pattern happens upon nuclear transfer and the re-
establishment of embryonic epigenetic characteristics and gene expression ensues, we are 
inclined to believe that some if not most of the oocyte reprogramming factors are 
chromatin or DNA modifiers. These oocyte proteins may explain the highly efficient 
nuclear reprogramming in SCNT.  
1.6  Aim of the project 
The mouse oocyte and early embryo are transcriptionally inactive. Hence, they 
fully depend on the maternal mRNAs and proteins stored during oocytes maturation to 
drive the onset of development. On the other hand, nuclear reprogramming using 
unfertilized oocyte can efficiently and faithfully reprogram somatic cells into pluripotent 
stem cells that are molecularly and functionality indistinguishable from ES cells derived 
from fertilized embryos. Hence, it is conceivable that oocyte may contain powerful 
factors that are useful to augment iPSC reprogramming close to the scale and quality that 
could be obtained in SCNT. 
The emphasis of this project was to use the iPSC reprogramming platform to 
identify oocyte-expressed factors that could potentiate factor-mediated somatic 
reprogramming, in particular, the efficiency and kinetics of the reprogramming process as 
well as the developmental potential or quality of the derived iPSCs. This project also 
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aimed to provide relevant mechanistic explanations underlying the observed 
enhancement effect of the oocyte factors that are effective in augmenting the 
reprogramming process.    
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CHAPTER 2: OOCYTE FACTORS TCL1 AND TCL1B1 ENHANCE IPSC 
REPROGRAMMING EFFICIENCY 
Oocytes contain factors that are powerful reprogramming players and many of 
them remain unexplored. In this chapter, I will examine the effect of ectopic expression 
of the selected oocyte factors on iPSC reprogramming and validate the positive effect of 
the oocyte factors in different cell types and reprogramming conditions. 
2.1  Results 
2.1.1  Selection of potential oocyte factors that may enhance iPSC reprogramming  
There are more than 700 murine oocyte proteins identified (Wang et al, 2010b; 
Zhang et al, 2009b). The stochastic nature and inconsistency of the viral vector-mediated 
iPSC reprogramming system (Hanna et al, 2009; Papapetrou et al, 2009), pose great 
challenge to the investigation of the role of oocyte factors in reprogramming with viral 
vector-mediated overexpression in a high throughput manner. Therefore, first level factor 
filtration was performed to select oocyte factors that fulfill one or more of the indicated 
criteria for testing (Table 1).  
First, the oocyte factors of interest have to be of high abundance in oocytes and/or 
show specific expression in oocytes. One of the extraordinary roles of the oocyte, upon 
fertilization, is to reprogram the paternal genome into a functional pronucleus (Mayer et 
al, 2000; Oswald et al, 2000). In addition, the oocyte is capable of reprogramming 
injected somatic nuclei to form blastocysts and its extract was also able to reprogram 
somatic cells (Alberio et al, 2005; Bian et al, 2009; Briggs & King, 1952; Campbell et al, 
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1996; Gurdon, 1960). Therefore, I postulate that these powerful reprogramming factors 
are likely present in abundance in order to initiate the above reprogramming processes.  
Other than oocytes, ESCs are also capable of reprogramming somatic nuclei in 
cell fusion assays (Tada et al, 1997a; Tada et al, 2001a) or via culture incubation method 
with ES cell extract (Taranger et al, 2005). In addition, one of the Yamanaka’s 
reprogramming factors, Oct4, is expressed in the oocyte and persists throughout 
development to the blastocyst stage (Ovitt & Scholer, 1998). Therefore, the second 
criterion is that the oocyte factors of interest are expressed in both oocytes and embryonic 
stem cells.  
Since the current direct reprogramming approach is mainly regulated by 
transcription factors, and the binding of transcription factors to the gene locus for 
transcription activation is largely determined by the chromatin structure (Jenuwein & 
Allis, 2001; Strahl & Allis, 2000), it is intriguing that oocyte factors that are chromatin or 
DNA modifiers have a higher potential to support nuclear reprogramming. Hence, the 











Table 1 | List of oocyte factors tested in iPSC reprogramming 
Gene 
Symbol  
Gene Name Criteria of selection 
OAS1e 2'-5'olygoadenylate synthetase 1E High abundance and oocyte specific protein (Paillisson et 
al, 2005; Zhang et al, 2009a) 
Nlrp5 NACHT, LRR and PYD domains-
containing protein 5 
High abundance protein in oocyte (Zhang et al, 2009a) 
Uhrf1 Ubiquitin-like, containing PHD and 
RING finger domains, 1 
High abundance protein in oocyte (Zhang et al, 2009a) 
PADI6 Protein-arginine deiminase type-6 High abundance and oocyte specific protein (Wright et al, 
2003; Zhang et al, 2009a); histone modification enzyme 
(Wang et al, 2010b) 
Pdia3 Protein disulfide-isomerase A3 
precursor 
High abundance oocyte protein in oocyte, expressed in 
oocyte and ESCs (Zhang et al, 2009a) 
Pdia6 Protein disulfide-isomerase A6 
precursor 
Oocyte-ESCs protein (Zhang et al, 2009a) 
TCL1 T-cell leukemia/lymphoma protein 1 Oocyte specific protein (Paillisson et al, 2005; Zhang et 
al, 2009a) 
TCL1b1 T-cell leukemia/lymphoma protein 1b1 Oocyte specific protein (Paillisson et al, 2005; Zhang et 
al, 2009a) 
Ddx19a ATP-dependent RNA helicase DDX19A Oocyte-ESCs protein (Zhang et al, 2009a) 
Ddx6 ATP-dependent RNA helicase DDX6 High abundance protein in oocyte; oocyte-ESCs protein 
(Zhang et al, 2009a) 
Brg1/Smar
ca4 
SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 4 
Chromatin modifier protein (Bultman et al, 2006) 
Npm2 Nucleoplasmin-2 Chromatin modifier protein (Betthauser et al, 2006) 
AURKA Aurora kinase A Highly expressed in oocyte and ESs cells (both mouse 
and human) (Kocabas et al, 2006) 
MSH2 MutS homolog 2 Highly expressed in oocyte and ESs cells (both mouse 
and human) (Kocabas et al, 2006) 
PHB1 Prohobitin-1 Oocyte-ESCs protein (Zhang et al, 2009a) 
AID Activation-Induced cytidine Deaminase  Oocyte-ESCs DNA modifier protein (Morgan et al, 2004) 
MBD4 Methyl-CpG-binding domain protein 4 Oocyte-ESCs  DNA modifier protein (Bhutani et al, 
2010a) 
Gadd45a Growth arrest and DNA-damage-
inducible protein GADD45 alpha  
Oocyte-ESCs  DNA modifier protein (Bhutani et al, 
2010a) 
Gadd45b GADD45 beta Same family as Gadd45a  
Gadd45g GADD45 gamma Same family as Gadd45a 
ERCC5 Excision repair cross-complementing 
rodent repair deficiency, 
complementation group 5 
DNA modifier protein (Menezo et al, 2007) 
Tpt1 Translationally-controlled tumor protein Oocyte factor activating plutipotency genes (Koziol et al, 
2007) 
RPA3 Replication protein A3 Oocyte-ESCs DNA modifier protein (Zhang et al, 2009a) 
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2.1.2  Oocyte factors TCL1 and TCL1b1 enhanced iPSC reprogramming efficiency 
To test the efficacy of the selected oocyte factors (Table 1) in enhancing iPSC 
reprogramming, I infected mouse embryonic fibroblasts (MEFs) carrying an endogenous 
Oct4-GFP reporter, first with retroviral vectors carrying Oct4, Sox2 and Klf4 (OSK), and 
then one day later with lentiviral vector carrying one of the selected oocyte factors 
(Figure 1-1a). Expressions of the transgenes were inducible by Doxycycline  (Dox). Dox 
was added to the culture media from day 5 to day 18 post-infection. At the end of the 
assay (18 day post-infection), colony counting was done based on Oct4-GFP and ESCs 
morphology (Figure 1-1b).  For all cloned factors, transcript levels were checked using 
quantitative PCR (qPCR) to ensure that overexpressions were at least 2-fold upon 
addition of Doxycycline (Dox) for 5 days (Figure 1-1c). Sequential transductions with 
different viral vectors were carried out in this assay to ensure maximum infection 
efficiency. This is because the efficiency of individual viral vector would decrease with 
the addition of more viral vectors into the transduction mixture as it increases the 
transduction competition between viral particles for cellular receptors. Since 
overexpression of oncogene cMyc can produce a lot of transformed or partially 
reprogrammed (non-ESCs like) colonies that would prevent accurate iPSC colony 
counting (Figure 1-2), cMyc was not included in the reprogramming cocktail used in this 
assay. 
Fully reprogrammed iPSC colonies were subcultured and characterized by PCR of 
genomic DNA to check for viral transgene integration. Immunofluorescence staining was 
also done to check for the expression of pluripotency markers (i.e. Nanog, SSEA-1 and 
Oct4). Figure 1-3 shows that iPSC clones are subculturable, showed positive integration 
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Figure 2-1 | Oocyte factors were overexpressed upon addition of Dox.  
a, Experimental layout and day numbering. b, iPSC colonies are Oct4-GFP positive and 
have ESCs like morphology. Scale bar: 200um. c, Expression check on all tested oocyte 
factors for upregulation of at least 2-fold against empty vector control upon addition of 
Dox for five days. Data correspond to the average and s.e.m. Error bars represent two 
biological replicates and three technical replicates in each sample. 
Day 22 2 3 1 4 
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Figure 2-2 | cMyc overexpression transformed fibroblasts.  
a, Representative images of reprogrammed (red arrows) and transformed colonies (blue 
arrows) derived from MEFs retrovirally infected with OSK or OSKC. Scale bar, 200µm. 
b, Representative images of iPSC colonies at lower magnification. 1 day after infection, 
OSK- and OSKC-infected cells were replated on inactivated feeders at 1.6x104 cells per 
well and 4x103 cells per well respectively. Transformed or partial reprogrammed colonies 


























Figure 2-3 | OSK-induced iPSC clones are subculturable, express pluripotency 
markers and show positive integration of trangenes.  
a, Representative images of primary and passaged iPSC colonies (3 passages). Scale bar 
200µm. b, Genomic integration check for Oct4, Sox2 and Klf4 transgenes by PCR on 
OSK-reprogrammed iPSC clone. c, Representative images of passaged iPSC clones. 
Scale bar 500µm. 
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Among the 19 tested oocyte factors (Table1), two showed markedly increased 
numbers of Oct4-GFP positive iPSC colonies (Figure 2-4) as compared to empty vector 
(EV) control. The 2 oocyte factors were TCL1 and TCL1b1 with an average of 2-fold and 




Figure 2-4 | Effect of oocyte factors in OSK-mediated iPSC reprogramming 
efficiency.  
Fold change of reprogramming efficiency of Oct4-GFP MEFs infected with OSK in pMX 
vectors plus individual oocyte factor in dox-inducible vector, against OSK plus dox-
inducible empty vectors (EV). Each data point was obtained in an independent 
experiment and corresponds to the average of three technical replicates. Two independent 





2.1.3  TCL1 and TCL1b1 overexpression also enhance reprogramming in highly 
efficient iPSC reprogramming systems 
TCL1 and TCL1b1 proteins are intracellular, non-enzymatic proteins that have 
been shown to bind AKT proteins, which are essential serine/threonine kinases that relay 
extracellular pro-growth and survival signals (Laine et al, 2000; Pekarsky et al, 2000). 
Instead of direct activation of kinases, TCL1 family may act to augment AKT1 activation 
by forming heteromeric complexes with AKT at the cytoplasmic membrane (Auguin et al, 
2004; French et al, 2002). The TCL1 family of genes was discovered due to its 
involvement in characteristic chromosome rearrangements in mature T-cell malignancy 
(Pekarsky et al, 1999; Stern et al, 1993; Sugimoto et al, 1999). Human and mouse TCL1 
loci appear as a complex tightly clustered genes. In mouse, there are 5 genes (TCL1b1-5) 
to human TCL1B albeit only with 30-40% similarity. In lower and non-mammalian 
eukaryotes, the absence of TCL1 gene family suggests that this gene family is recently 
acquired in mammalian physiology.  
In mice, Tcl1 and the genes Tcl1b1 to Tcl1b5 are expressed in oocytes and early-
cleavage embryos. Tcl1 is detected during early to mid-gestation and also in fetal liver, 
thymus, bone marrow and the yolk sac. Tcl1 is also expressed during B-cell and T-cell 
development (Hallas et al, 1999; Minami et al, 2001; Narducci et al, 2002). In human, 
expression of TCL1-family genes has not been evaluated in early embryogenesis. 
Nevertheless, TCL1A and TCL1B are expressed in several fetal tissues, for instance, liver, 
kidney, thymus and peripheral blood lymphocytes (Hallas et al, 1999; Narducci et al, 




OSK-mediated reprogramming is far less efficient as compared to reprogramming 
with additional cMyc oncogene overexpression (Nakagawa et al, 2008; Nakagawa et al, 
2010; Wernig et al, 2008b). On the other hand, highly efficient iPSC reprogramming is 
possible when tumor suppresser p53 is suppressed (Banito et al, 2009; Hong et al, 2009; 
Kawamura et al, 2009; Li et al, 2009a; Marion et al, 2009; Utikal et al, 2009). I next 
sought to test if cMyc overexpression or p53 suppression will mask or abolish the 
enhancement effect of TCL1 and TCL1b1.  
In OSK plus cMYC (OSKC)-mediated reprogramming system, significant 
enhancement effects (p<0.01) by TCL1 and TCL1b1 were observed. To ensure more 
reliable induction, the MEFs used here contained stably integrated reverse tetracycline 
transactivator (rtTA, for Dox induction) and the transgenes were carried on a Dox-
inducible polycistronic vector (Figure 2-5).  
Furthermore, TCL1 and TCL1b1 overexpression also resulted in significant 
increase in colony number (p<0.01) in p53-null MEFs that were reprogrammed with 
OSK-overexpression (Figure 2-6). Reprogramming efficiency in p53-null MEFs was 
improved from 3.8% to 9.1% (p<0.01) and to 9% (p<0.01) for TCL1 and TCL1b1 

























Figure 2-5 | TCL1 and TCL1b1 over-expressions also enhance OSKC-mediated 
iPSC reprogramming efficiency.  
a, Total colony number per well derived from primary rtTA MEFs lentivirally infected 
with four factors plus empty vector (EV) or the indicated oocyte factors. Data correspond 
to the average and s.e.m.. Error bars represent three technical replicates in two 
independent experiments. ** P < 0.01. b, Representative images of AP stained colonies, 
derived from rtTA MEFs lentivirally infected with OSKC and indicated oocyte factor  in 






































Figure 2-6 | Enhancement of reprogramming by TCL1 and TCL1b1 over-expression 
may be independent of p53.  
a, Total colony number per well derived from primary p53 null MEFs retrovirally 
infected OSK plus empty vector (EV) or the indicated oocyte factors. Data correspond to 
the average and s.e.m.. Error bars represent two biological and three technical replicates. 
** P < 0.01. b, Representative images of AP stained colonies, derived from p53 null 
MEFs retrovirally infected with OSK and indicated oocyte factor  in Dox inducible 











2.1.4  Endogenous TCL1 supported iPSC reprogramming 
To assess whether endogenous TCL1 or TCL1b1 is important for iPSC 
rerpogramming, I tested the effects of knocking down TCL1 or TCL1b1 in iPSC 
reprogramming assay. 
Sets of four small hairpin RNAs (shRNAs) were constructed on lentiviral vectors 
against each of Oct4, TCL1 and TCL1b1. Their knockdown efficiencies were first tested 
in MEFs undergoing OSK reprogramming (Figure 2-7). On day 15 of reprogramming, 
when endogenous Oct4 and TCL1 were normally upregulated, expression results by 
qPCR showed that shRNA3 (shOct4-3) for Oct4 resulted in the strongest expression 
knock down of Oct4 expression and inhibition in iPSC reprogramming (Figure 2-7a and 
2-7b). Therefore, shOct4-3 was used as a control for assessing knock down effect of 
TCL1 in iPSC reprogramming assay. For TCL1, shRNA3 (shTCL1-3) and shRNA4 
(shTCL1-4) were effective in knocking down the expression of TCL1 by ~50% (Figure 2-
7c) and were used in subsequent experiments. On the other hand, the 4 shRNA constructs 
against TCL1b1 were either not effective or specific in knocking down TCL1b1 
expression (data not shown).  
I then introduced both shRNAs (shTCL1-3 and shTCL1-4) to knock down TCL1  
in wild type and p53 null MEFs undergoing OSK-mediated reprogramming.  A 90% 
TCL1 expression knock down was observed in both wild type and p53 null MEFs (Figure 
2-8a). Knocking down TCL1 during the course of OSK-mediated iPSC reprogramming 
decreased the reprogramming efficiency around 60% (p<0.01) and 70% (p<0.001) in 
wild type and p53 null MEFs respectively (Figure 2-8b and 2-8c). More importantly, the 
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degree of inhibition by TCL1 knock down was similar to that of Oct4 knock down 




























Figure 2-7 | Knock down efficiency of shRNA constructs for TCL1 and Oct4. 
WT MEFs were infected with infected with indicated shRNA followed by OSK retroviral 
transduction. Fifteen days after viral transduction, the transcript expression level of a, 
Oct4 and c, TCL1 were analysed. All expression data correspond to the average and s.e.m. 
Expression levels were normalized against GAPDH. Error bars represent three technical 
replicates in each sample. b, Total colony number per well derived from primary wild 
type MEFs lentivirally infected with OSK plus indicated shRNA. Data correspond to the 





























































Figure 2-8 | Knock down of TCL1 decreased reprogramming efficiency. 
a, MEFs were infected with indicated shRNA followed by OSK retroviral transduction. 
Fifteen days after viral transduction, the transcript expression level of TCL1 was analyzed. 
All expression data correspond to the average and s.e.m. Expression levels were 
normalized against GAPDH. Error bars represent three technical replicates in each 
sample. b, Fold change of reprogramming efficiency of primmary wild type (WT) CF1 
MEFs and c, primary p53 null MEFs, retrovirally infected with OSK plus  control or the 
indicated shRNAs. Data correspond to the average and s.e.m. Error bars represent three 
technical replicates in two independent experiments. **p<0.01 and ***p<0.001. 
Representative images of AP stained colonies, derived from d, WT MEFs and e, p53 null 
MEFs, retrovirally infected with OSK and indicated shRNAs. Tissue culture plate well 
diameter is indicated.  
 
2.1.5  Enhancement effects of TCL1 and TCL1b1 in iPSC reprogramming were 
conserved in human iPSC reprogramming 
Despite many apparent similarities between mouse and human systems, results 
obtained from the mouse system cannot always be directly extrapolated to the human 
study. In addition to distinct culture requirements for maintaining pluripotency in mouse 
and human ESCs (Humphrey et al, 2004; Levenstein et al, 2006; Smith et al, 1988; 
Williams et al, 1988; Xu et al, 2005),  they appeared to show some dissimilarities in the 
context of somatic reprogramming. For instance, Nanog appeared to improve the 
efficiency in human but not in mouse iPSC reprogramming (Hanna et al, 2009; Yu et al, 
2007).  
TCL1 and TCL1b1 are present in abundance in mouse and human oocytes 
(Kocabas et al, 2006; Wang et al, 2010b; Zhang et al, 2009b). Since murine TCL1 and 
TCL1b1 share less than 50% homology with human proteins (Hallas et al, 1999; 
Narducci et al, 1997) and human iPSC cells are an important source for therapeutic 
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application, I sought to examine if enhancements by TCL1 and TCL1b1 were also 
conserved in human iPSC reprogramming.  
A feeder free human iPSC reprogramming system (Fig 2-9a) was set up to access 
the effect of ectopically expressed TCL1 and TCL1b1 on human iPSC reprogramming 
efficiency. The quantitative readout of efficiency was based on colony morphology and 
expression of the stringent pluripotency marker, Tra1-60 (Figure 2-9b) (Chan et al, 2009; 
Lowry et al, 2008).  
In this system, the overexpression of human TCL1 and TCL1b (Fig 2-10b) 
increased the numbers of iPSC colonies by 6 fold (p=0.05) and 9 fold (p=0.01) 
respectively (Fig 2-10a and 2-10c). On average, reprogramming efficiency was improved 






Figure 2-9 | The measurement of human iPSC reprogramming efficiency by AP and 
Tra1-60 staining. 
a, Experimental layout and day numbering. b, Representative images of human iPSC 
colonies stained positive with Tra1-60 and alkaline phosphatase. Propidium iodide was 





























































Figure 2-10 | iPSC reprogramming efficiency enhancement by TCL1 and TCL1b1 
overexpression is reproducible in the human system. 
a, Expression level of human TCL1 and TCL1b upon addition of Dox in lentivirally 
infected HDFs for five days. Expression levels were normalized against YWHAZ. Data 
corresponds to the average and s.e.m. Error bars represent two biological replicates and 
three technical replicates in each sample. b, Fold change of reprogramming efficiency of 
human dermal fibroblasts (HDFs) retrovirally infected OSKC plus empty vector (EV) or 
the indicated oocyte factors. Data correspond to the average and s.e.m.. Error bars 
represent three technical replicates in two independent experiments. ** P=0.01 and * 
P=0.05. c, Representative images of bright-field (left, arrowed), Tra-1-60 (middle, 
arrowed) and AP stained colonies (right), derived from HDFs retrovirally infected with 
OSKC and indicated oocyte factor  in Dox inducible vector, at day 21 after addition of 
Dox. Scale bar, 2mm.  
 
 
2.1.6  TCL1 and TCL1b1 overexpression accelerated early onset of fully reprogrammed 
iPSC cells 
Since TCL1 and TCL1b1 overexpression increased the efficiency of iPSC 
reprogramming, I sought to examine their role in the kinetics of iPSC reprogramming 
during early reprogramming by performing FACS analysis on infected Oct4-GFP MEFs 
based on early SSEA-1 and late Oct4-GFP markers (Brambrink et al, 2008).  
In agreement with other study (Maekawa et al, 2011), OSK-mediated 
reprogramming yielded less than 0.5% Oct4-GFP positive reprogrammed cells at 5 dpi 
(Figure 2-11a). In addition, cMyc overexpression only resulted in higher Oct4-GFP 
positive cell population relative to empty vector control at 7 dpi but not earlier (Corey et 
al, 2012). In contrast, the overexpression of TCL1 and TCL1b1 increased the early onset 
of Oct4-GFP positive cells relative to empty vector control at day 3 and day 5 
respectively (Figure 2-11b, 2-11d and 2-11e).  
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Intriguingly, the overexpression of cMyc increased significantly the SSEA-1 
positive cells as compared to EV and other factors since 3 dpi. However, even at 7 dpi, 
the majority of the SSEA-1 positive cells were not further reprogrammed into Oct4-GFP 
positive cells and the Oct4-GFP positive cell population still remained lower than that 
derived with TCL1 and TCL1b1 overexpression (Figure 2-11d and 2-11e). This may be 
explained by the appearance of partial reprogrammed colonies (Oct4-GFP-) (non-ESCs 
like colonies) in significantly greater proportion than fully reprogrammed colonies (Oct4-
GFP+) in cMyc overexpression condition (Figure 2-11e). In this assay, fully 
reprogrammed cell population, which was positive for both markers, Oct4-GFP+ and 


























































Figure 2-11 | TCL1 and TCL1b1 overexpression accelerated iPSC reprogramming process. 
Time-course analysis of OSK-infected MEFs carrying Oct4-GFP reporter for the expression of   a, Oct4-GFP (percentage) and b, 
Oct4-GFP (fold change) c, SSEA-1 (fold change) at 3 days post-infection (dpi), 5 dpi and 7 dpi using FACS analysis. Data correspond 
to the average of three technical replicates for each sample in two independent experiments. d, Representative FACS contour plots of  
the expression of SSEA-1 and Oct4-GFP on samples from b and c. e, Representative images of OSK-infected MEFs from b and c. 
Oct4-GFP is shown in green. Scale bar, 200µm.  
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2.2  Discussion 
To specifically define oocyte factors that may contribute to reprogramming via 
SCNT, I have undertaken the screening of 19 oocyte-expressed factors to identify 
individual factors that also augment iPSC reprogramming. To assay for a reprogramming 
enhancement effect, the overexpression of OSK without cMyc was carried out as this 
system enriches for fully reprogrammed Oct4-GFP positive iPSC colonies (Figure 1-1) 
and therefore it is more suitable for colony counting with a lower background of partially 
reprogrammed or transformed colonies (Han et al, 2010; Maekawa et al, 2011).  
Furthermore, it is a screening system with better sensitivity to test for factors that may 
augment iPSC reprogramming efficiency by increasing the Oct4-GFP positive colony 
number. Of the 19 oocyte factors tested, I found that the overexpression of two factors—
TCL1 and TCL1b1—appreciably enhanced iPSC cell reprogramming efficiency 2-fold to 
3-fold (Figure 1-3). Strikingly, TCL1 and TCL1b1 overexpression showed synergistic 
enhancement on iPSC reprogramming efficiency (p<0.01) when co-overexpressed with 
cMyc (Figure 2-4) or when p53 was suppressed (Figure 2-5). Furthermore, TCL1 and 
TCL1b1 reproducibly augmented iPSC reprogramming efficiency when infected MEFs 
were cultured in ESC media supplemented with a proprietary chemically defined ‘Knock-
Out Serum Replacement’ (KSR) which contains ascorbic acid (Figure 1-3 to 2-5). 
Ascorbic acid has been shown to improve reprogramming efficiency by 10-fold by 
suppressing ROS production or cell senescence (Esteban et al, 2010). These findings 
suggest that the oocyte factors TCL1 and TCL1b1 promote reprogramming irrespective 
of cMyc, p53 or ascorbic acid-induced cellular changes.  
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More importantly, the degree of inhibition on reprogramming by TCL1 expression 
knock down was similar to that of Oct4 knock down (Figure 2-8). This showed that, 
similar to Oct4, endogenous TCL1 is important and has a supportive role for iPSC 
reprogramming. In fact, TCL1 is an important self-renewal regulator that is integrated 
into an interconnected transcriptional network in maintaining pluripotency of ESCs 
(Ivanova et al, 2006). Furthermore, its expression is directly regulated by pluripotency 
regulators (i.e. Oct4, Klf5 and Zfx) and Oct4/TCL1/AKT1 signaling is shown to be 
important in regulating apoptosis in mouse ESCs (Ema et al, 2008; Galan-Caridad et al, 
2007; Hu et al, 2008; Matoba et al, 2006). Therefore, suppression of such an important 
self-renewal regulator could impede the re-establishment of stemness in somatic cells.  
Since the ultimate goal of iPSC reprogramming is to enable the patient specific 
studies and cell-based therapy, it is important to show that the enhancement effects of 
TCL1A and TCL1b are reproducible in human iPSC reprogramming. The present study 
showed that the overexpression of TCL1A and TCL1b augmented iPSC reprogramming 
efficiency by 6-fold to 9-fold (Figure 2-10).  
In this study, the potential of reprogramming factor replacement (i.e. Oct4, Sox2, 
Klf4 in mouse and Oct4, Sox2, Klf4, cMyc in human) by TCL1/TCL1A and 
TCL1b1/TCL1b was also tested. However, the two oocyte factors failed to replace any of 
the reprogramming factors in mouse and human iPSC reprogramming (data not shown). 
In spite of this, one study showed that TCL1A in combination with Sox2 and Myc 
overexpression could reprogram human fibroblasts, albeit partially, to become stem cell-
like (Picanço-Castro et al, 2011). This can be explained by the failure of TCL1 
overexpression alone to re-capitulate pluripotency in ESCs without Oct4 (Matoba et al, 
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2006). In addition, the partially reprogrammed ESC-like cells were derived from 
fibroblasts that expressed Klf4, at a level that was even higher than that of human ESCs 
thus allowing for initiation of reprogramming without exogenous Klf4 (Picanço-Castro et 
al, 2011).  
When the effects of TCL1 and TCL1b1 on iPSC reprogramming kinetics were 
accessed based on SSEA-1 marker, the overexpression of TCL1 and TCL1b1 increased 
the SSEA-1 positive population by more than 2-fold relative to empty vector control at as 
early as 5 dpi (data not shown).  Interestingly, cMyc overexpression markedly increased 
the SSEA-1 positive population more than any other condition at as early as 3 dpi but the 
Oct4-GFP positive cell population did not increased proportionally to the SSEA-1 
positive cell population resulting in a predominantly partial reprogrammed cells (Figure 
2-11). These observations support earlier studies that demonstrated cMyc overexpression 
in combination with OSK resulted in higher reprogramming efficiency albeit low quality 
(Han et al, 2010; Maekawa et al, 2011; Nakagawa et al, 2008; Nakagawa et al, 2010; 
Wernig et al, 2008b). On the other hand, Oct4-GFP positive cells were detected as early 
as day 5 dpi and higher populations were detected in TCL1 and TCL1b1 overexpression 
conditions relative to empty vector control (Figure 2-11a, 2-11c and 2-11d). However, 
this distinct cell population was SSEA-1 negative as opposed to fully reprogrammed 
iPSC cells marked by double positive for SSEA-1 and Oct4-GFP (Brambrink et al, 2008). 
Microscopic observations at 6 dpi (Figure 2-11e) confirmed that the observed Oct4-GFP 
positive cells adopted epithelial morphologies of rounded cells in aggregates that mark 
early reprogrammed cells (Li et al, 2010). This SSEA- Oct4-GFP+ cell population may 
therefore be a unique feature of OSK-mediated reprogramming. So far, SSEA-1 and 
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Oct4-GFP double profiling has not been studied for OSK-infected MEFs at early 
reprogramming phase. To validate that these early Oct4-GFP positive cells are truly early 
reprogrammed cells and are SSEA-1 negative, live imaging of infected cells with SSEA-
1 and other epithelial markers (e.g. E-cadherin, beta-catenin and pan-cytokeratin) at early 
time points would be critical.  
In summary, this chapter has highlighted the role of TCL1 and TCL1b1 in 







CHAPTER 3: TCL1 AND TCL1B1 IMPROVE THE QUALITY OF IPSC CELLS 
After accessing the role of TCL1 and TCL1b1 on the efficiency and kinetics of  
the iPSC reprogramming process, I will extend my study to their role in the quality of 
reprogrammed iPSC cells. In this chapter, different strategies used to examine the quality 
of iPSC cells will be discussed. 
3.1  Results 
3.1.1  TCL1 and TCL1b1 favored the formation of fully reprogrammed iPSC cells 
It is known that the majority of iPSC cells (>95%) are poor in quality and 
incapable of tetraploid complementation which constitutes the most stringent assay for 
developmental potential (Eggan et al, 2001; Nagy et al, 1990; Stadtfeld et al, 2010a). 
Since TCL1 and TCL1b1 have a profound positive effect on the efficiency of iPSC cell 
generation, it would be interesting to study if they have any influence on the quality of 
iPSC reprogramming.  
During conventional iPSC reprogramming, the resultant colonies consist of partial 
and fully reprogrammed colonies. In the preliminary study, the roles of TCL1 and 
TCL1b1 in the quality of iPSC were tested to see if they could increase the proportion of 
fully reprogrammed colonies relative to total ESC-like colonies. Strikingly in OSK-
mediated reprogramming, as compared to empty vector control, TCL1 and TCL1b1 
overexpression significantly increased fully reprogrammed colonies marked by Oct4-
GFP positive relative to the total AP positive colonies (p<0.5) (Figure 3-1a). The colony 
assay was done on day 18 post-infection. Moreover, during early phase of 
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reprogramming, the overexpression of TCL1 and TCL1b1 resulted in higher proportion of 
fully reprogrammed iPSC cells (Oct4-GFP+) relative to partial reprogrammed iPSC cells 
(SSEA+ Oct4-GFP-) at day 3 and day 7 respectively (Figure 3-1b). In contrast, cMyc 
overexpression markedly delayed the formation of fully reprogrammed iPSC cells 















Figure 3-1 | TCL1 and TCL1b1 overexpression favored the formation of fully 
reprogrammed iPSCs.  
a, Percentage of the total Oct4-GFP positive relative to the total AP positive iPSC 
colonies. Data corresponds to the average and s.e.m. Error bars represent three technical 
replicates in two independent experiments. **p<0.05 b, Ratio of fully reprogrammed 
cells (percentage) marked by Oct4-GFP positive relative to partial reprogrammed cells 
(percentage) marked by SSEA-1 positive. Data was obtained with FACS and corresponds 
to the average and s.e.m. Error bars represent three technical replicates in two 
independent experiments. All iPSC colonies were derived from Oct4-GFP MEFs infected 






3.1.2  TCL1 and TCL1b1 favored the formation of iPSC clones with high quality 
markers expression 
Global expression profiling is often not sufficiently sensitive to detect the inherent 
variations among iPSC clones as compared to analyzing just a small subset of genes that 
are important for pluripotency and self-renewal of ESCs (Han et al, 2010; Liu et al, 2010; 
Okita et al, 2007; Stadtfeld et al, 2010a). Furthermore, these inherent differences among 
iPSC clones have been shown to be attenuated with extensive passaging and the potential 
impact of these differences on the developmental potential of iPSC clones remain 
unexplored (Chin et al, 2009; Chin et al, 2010; Ohi et al, 2011; Polo et al, 2010).  
Since gene expression profiling of iPSC clones upon passaging is labor intensive 
and there is a selection bias towards clones that have survived upon colony picking, I 
sought to establish a higher throughput expression assay that allowed the expression 
profiling of primary iPSC clones without passaging and used this assay to assess if 
overexpression of TCL1 and TCL1b1 could improve the quality of iPSC cells. In this 
assay, infected MEFs were cultured in ESCs media with ES FBS, Doxycycline , and 
puromycin throughout the period of reprogramming. Then to ensure complete silencing 
of the lentiviral transgenes, Doxycycline  was removed from the media 3 days before 
colony picking. On day 21 dpi, fully reprogrammed primary iPSC colonies (Oct4-GFP+) 
were picked with minimal feeder contamination (Figure 3-2) and gene expression assay 
was performed on individual picked colonies.  
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A panel of expression markers that are associated with pluripotency and 
developmental potential of iPSCs was used to assess the quality of iPSCs. Expression 
markers used were namely Nanog, Rex1, Tbx3 and the Dlk1–Dio3 gene cluster.  
It has been shown that ESCs in culture are heterogeneous with individual cells 
displaying dynamic phenotypes (Hayashi et al, 2008; Stewart et al, 2006) and also 
variable levels of the ESC state (e.g. Nanog, Stella, and Rex1) despite the maintenance of 
other pluripotency markers like Oct4 at consistent levels (Chambers et al, 2007; Toyooka 
et al, 2008). Nanog is one of the core regulators of pluripotency and it is regulated by 
LIF-Stat3 signaling which maintains the self-renewal of ESCs (Boyer et al, 2005; 
Chambers et al, 2003; Loh et al, 2006; Mitsui et al, 2003). Studies have shown that Rex1- 
positive cells highly expressed inner cell mass markers, for example, Nanog, Tbx3 and 
Klf4 (Pelton et al, 2002; Rogers et al, 1991). Furthermore, its expression can be used to 
distinguish the mature fully reprogrammed iPSC cells from the partially reprogrammed 
cells (Chan et al, 2009). Similar to Klf4, Tbx3 has been shown to mediate LIF-Stat3 
signaling to the core pluripotency circuitry and to be indirectly associated with the 
maintenance of pluripotency (Lu et al, 2011; Niwa et al, 2009). In addition, Han et al. 
have shown that high Tbx3 expression improves the quality of iPSC cells by enhancing 
their germ-line competency in mouse (Han et al, 2010). More recently, Stadtfeld et al. 
have demonstrated that ESCs and iPSCs are essentially indistinguishable transcriptionally 
except for a few maternally expressed non-coding transcripts, namely Gtl-2 and Rian, 
from the imprinted Dlk1-Dio3 gene cluster (Liu et al, 2010; Stadtfeld et al, 2010a). In 
addition, the study has shown that only iPSC clones with high expression of Gtl-2/Meg3  
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or Rian show full developmental potential and are capable of tetraploid complementation 



























Figure 3-2 | iPSC colonies were picked with minimal feeders contamination. 
The representative images of iPSC colonies in adherent and detached form upon colony 
picking. Scale bar, 200µm. Blue marks indicate Oct4-GFP positive colonies. 
 
Interestingly, iPSC clones that were derived with TCL1 overexpression showed 
significantly higher expression of Rex1, Tbx3 and Gtl-2 (p<0.05) while clones generated 
with TCL1b1 overexpression showed significantly higher expression level of Rex1, Tbx3, 





Nanog and Rian (p<0.05) (Figure 3-3). Stadtfeld et al. claimed that iPSC clones can be 
classified into Gtl2-ON and Gtl2-OFF based on the level of Gtl-2 or Rian expression 
(Stadtfeld et al, 2010a; Stadtfeld et al, 2012). However, there was no distinct pattern 
observed for the Gtl-2 or Rian expression profile in the primary iPSC clones in the 
present study that allowed for such classification. Instead, I classified the iPSC clones 
according to single gating (Gtl2LOW, RianLOW, Gtl2HIGH or RianHIGH) and double gating 
(Gtl2LOW/RianLOW or Gtl2HIGH/RianHIGH) using mean expression value of the EV control 
as reference (Figure 3-3). Table 2 indicates that TCL1 or TCL1b1 overexpression resulted 
in higher population of double Gtl-2HIGH/RianHIGH (44% for TCL1 and 38% for TCL1b1) 
































Figure 3-3 | iPSC clones derived with TCL1 and TCL1b1 overexpression showed 
higher expression of quality markers. 
WT MEFs were infected with OSK retrovirus followed by lentiviral empty vector or 
indicated oocyte factors. iPSC colonies were formed in the presence of puromycin 
selection and picked on 21dpi. The transcript level of Rex1, Tbx3, Nanog,  GTL-2 and 
Rian were analyzed. All expression data (log2) correspond to the average and s.e.m. 
Expression levels were normalized against GAPDH. Error bars represent three technical 







Table 2 | iPSC clones derived with TCL1 or TCL1b1 overexpression increased 
population of Gtl2HIGH/RianHIGH iPSC clones.  
iPSC clones from figure 3-3 were classified into Gtl2LOW/RianLOW and Gtl2HIGH/RianHIGH 
based on the mean value of Gtl-2/Rian expression in the OSK+EV condition. For 
instance, clones that expressed Gtl-2/Rian lower than the mean value will be classified as 
Gtl2LOW/RianLOW and vice versa. For Gtl2HIGH +RianHIGH  iPSC clones, both Gtl2 and 











% Total clones 
(Gtl2HIGH) 
% Total clones 
(RianHIGH) 
% Total clones 
(Gtl2HIGH +RianHIGH) 
Empty vector (EV) 47.6 26.3 21.4 
TCL1 85.7 65 44.4 





To date, there are only a few factors or compounds that can improve both 
efficiency and quality of iPSC reprogramming (Esteban et al, 2010; Maekawa et al, 2011; 
Silva et al, 2008; Stadtfeld et al, 2012). The majority of the identified pro-reprogramming 
factors have been shown to improve either the efficiency or quality of iPSCs. Moreover, 
some factors like cMyc and p53, despite being able to accelerate iPSCs formation, these 
factors failed to increase the population of fully reprogrammed iPSCs (Han et al, 2010; 
Maekawa et al, 2011; Nakagawa et al, 2008; Nakagawa et al, 2010; Smith et al, 2010; 
Wernig et al, 2008b). Recently, another maternal transcription factor, Glis1 was also 
found to favor the formation of mature human iPSC colonies (Maekawa et al, 2011). 
Despite the fact that Glis1 failed to increase significantly the number of fully 
reprogrammed iPC colonies relative to OSK alone, TCL1 and TCL1b1 overexpression 
successfully increased Oct4-GFP positive colonies by 20% and 12% respectively (p<0.05) 
relative to EV control (Figure 5a). When reprogrammed cells were examined at the early 
reprogramming stage (day3 to day 7), the proportion of Oct4-GFP positive cells relative 
to SSEA-1 positive cells had also increased at day 3 for TCL1 and at day 7 for TCL1b1 
(Figure 5b). In contrast, cMyc overexpression significantly suppressed the formation of 
fully reprogrammed Oct4-GFP positive cells even at Day7 (Figure 5b). These 
observations support the earlier studies that have demonstrated that cMyc overexpression 
in combination with OSK resulted in higher reprogramming efficiency albeit low quality 
(Han et al, 2010; Maekawa et al, 2011; Nakagawa et al, 2008; Nakagawa et al, 2010; 
Wernig et al, 2008b). Therefore, TCL1 and TCL1b1 appear to favor the formation of 
fully reprogrammed cells marked by Oct4-GFP positive. These findings also highlight 
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that oocytes contain powerful reprogramming factors that can augment the direct iPSC 
reprogramming process with efficiency and even quality closer to that of SCNT nuclear 
reprogramming.  
Remarkably, even though only iPSC colonies that express Oct4-GFP, a marker 
for fully reprogrammed iPSCs, were picked for expression analysis, significant 
expression differences were detected among clones derived using different factors in 
addition to OSK (Figure 3-3). This highlights again that Oct4 expression alone is not 
sufficient for the quality assessment of iPSCs. This is supported by the facts that Oct4 is 
homogenously expressed in a heterogeneous ESCs population in culture and that 
differential developmental potentials of Oct4-expressing ESCs are determined by Rex1 
expression (Toyooka et al, 2008). More importantly, Oct4-GFP expressing iPSC clones 
show vast differences in developmental potential depending on the use of reprogramming 
factor combination (Han et al, 2010).  
In the primary clonal expression assay, both TCL1 and TCL1b1 significantly 
(p<0.05) increased the expression of Rex1 and Tbx3 in iPSC primary clones (Figure 3-3). 
As mentioned earlier, Rex1 and Tbx3 are markers that are associated with the 
pluripotency and developmental potential of iPSCs (Chan et al, 2009; Han et al, 2010; 
Toyooka et al, 2008). The correlation of TCL1 and Rex1 has been implicated in ESCs, in 
a study in which TCL1 is highly expressed in Rex1-positive mouse ESCs (Toyooka et al, 
2008). Furthermore, studies have shown that Rex1-positive cells highly express inner cell 
mass markers e.g. Nanog, Tbx3 and Klf4 (Pelton et al, 2002; Rogers et al, 1991; Toyooka 
et al, 2008). 
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In addition to Rex1 and Tbx3, TCL1 and TCL1b1 overexpression also increased 
the expression level of Gtl-2 and Rian respectively (Figure 3-3). As opposed to the 
previous studies in which the iPSC clones could be classified into Gtl2ON/RianON and 
Gtl2OFF/RianOFF, there were no clear distinctions in the expression patterns of Gtl-2 
and Rian observed in the primary iPSC clones in present study. This could be explained 
by the fact that the iPSC clones used in previous studies were of late passage and hence 
may show distinct expression patterns from primary iPSC clones (Plath & Lowry, 2011). 
When the iPSC clones were classified into double Gtl2LOW/RianLOW and 
Gtl2HIGH/RianHIGH, TCL1 and TCL1b1 overexpression again increased the population of 
Gtl2HIGH/RianHIGH iPSC clones relative to empty vector control (Table2). This strongly 
suggests that transgenic TCL1 and TCL1b1 upregulated Gtl-2 or Rian expression and 
resulted in a greater population of Gtl2HIGH/RianHIGH iPSCs. Recently, ascorbic acid was 
found to remarkably improve the quality of iPSC clones by preventing the 
hypermethylation and thus the silencing of the Dlk1-Dio3 gene locus from which Gtl-
2/Meg3 and Rian RNA is transcribed (Stadtfeld et al, 2012).  In addition, ascorbic acid 
also significantly improves iPSC reprogramming efficiency by correcting detrimental 
ROS production in OSK-mediated reprogramming (Esteban et al, 2010). Studies have 
shown that the repression of maternal Dlk1-Dio3 transcripts seems to occur in two 
distinct phases, with transcriptional downregulation at the initial reprogramming stage 
followed by acquisition of aberrant DNA methylation and stable gene silencing at the end 
of the process (Stadtfeld et al, 2012). Therefore, to gain insights into the mechanism 
underlying the upregulation of Gtl-2 and Rian expression by TCL1 or TCL1b1 
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overexpression, the methylation patterns of Dlk1-Dio3 gene locus in Gtl2LOW/RianLOW 
and Gtl2HIGH/RianHIGH primary iPSC clones merit further investigation.  
For TCL1b1 overexpression, the significant upregulation of Nanog expression in 
iPSC clones appears to suggest that TCL1b1 may augment LIF-Stat3 signaling, one of 
the pluripotency signaling pathways that regulates Nanog expression in mouse ESCs 
(Niwa et al, 2009). TCL1b1 overexpression is able to improve the quality of iPSCs but 
interestingly, the enhancement effect of TCL1b1 on iPSC reprogramming efficiency 
appeared to be suppressed by unknown inhibitory factors in the embryonic stem-screened 
fetal bovine serum (ES FBS) (Figure 4-8b, in next chapter). In agreement with the facts 
that Nanog is a downstream target of TCL1 and Tbx3 (Ivanova et al, 2006), the 
overexpression of TCL1 also moderately increased Nanog expression (p=0.08) in primary 
iPSC clones (Figure 3-3).  
Interestingly, two of the quality markers, Tbx3 and GTL-2, were expressed higher 
in ESCs than iPSC primary clones. This suggests three possible explanations. Firstly, the 
overexpression of OSK alone is not sufficient to reprogram somatic cells fully into 
pluripotent stem cells that are identical to ESCs but rather a unique population of 
pluripotent-like cells (Chin et al, 2009). Secondly, continual reprogramming that may 
occur upon iPSC clone subculturing in ESC media could cause additional changes in the 
expression profile of iPSC clones. For instance, Chin et al. found that a large set of 
somatic genes were incompletely silenced in the early passaged iPSC clones but not 
when the clones were passaged for some time (Chin et al, 2009). Thirdly, it is also 
possible that these ESC lines have been adapted in feeder-free culture for a period of time 
(>10 passages) and such tissue culture selection has led to either enrichment for a 
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subpopulation of cells or expression changes of a subset of genes in the cells (Buehr et al, 
2003; Hayashi et al, 2008; Ramos-Mejia et al, 2012). Nevertheless, a higher number of 
iPSC clones derived from each reprogramming condition should be included into future 
analysis before a more conclusive finding can be made.  
In this chapter, I have shown that TCL1 and TCL1b1, in addition to augmenting 
iPSC reprogramming efficiency, also appeared to improve the developmental potential, 
thus, the quality of iPSCs. The roles of TCL1 and TCL1b1 on the improvement of the 
quality or developmental potential of iPSCs need to be validated functionally with 
tetraploid complementation. Since they are the cofactors that function to modulate the 
activities of multiple functional proteins (i.e. AKT family proteins, c-Jun, JunB, and c-
Fos)  (Laine et al, 2002; Pekarsky et al, 2000; Pekarsky et al, 2008), the mechanism 
underlying such augmentation is an interesting area for further investigation.  
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CHAPTER 4: THE ENHANCEMENT EFFECTs OF TCL1 AND TCL1B1 
INVOLVE DIFFERENT MECHANISMS 
The results of my study so far have clearly shown that TCL1 and TCL1b1 
overexpression significantly augment iPSC reprogramming by enhancing its efficiency, 
kinetics and quality. In this chapter, I will examine the possible mechanisms 
underpinning the observed enhancements.  
4.1  Results 
4.1.1 TCL1 and TCL1b1 show different expression patterns 
Since TCL1 and TCL1b1 support somatic cell reprogramming, it would be 
important to determine if their endogenous expression levels are induced during the 
reprogramming through the overexpression of OSKC and remain elevated in iPSCs.  
When cell type specific expression of TCL1 and TCL1b1 in ovaries, pluripotent 
ESCs and somatic MEFs was measured, distinct patterns were observed (Figure 7-1). 
TCL1 showed negligible expression in differentiated MEFs but its expression was 
enriched in ovaries that store oocytes and in ESCs. On the other hand, TCL1b1 
expression was only enriched in ovaries. During the course of OSKC-mediated 
reprogramming in rtTA MEFs, endogenous TCL1 expression was gradually upregulated 
from day 7 onwards, a pattern similar to that of Nanog (Figure 4-2). On the other hand, 
TCL1b1 expression was undetectable throughout the course of the OSKC overexpression 





Figure 4-1 | TCL1 and TCL1b1 show different cell type specific expression patterns.  
Endogenous expression level of murine TCL1 and TCL1b1 in different cell types. 
Expression levels were normalized against GAPDH.  Data corresponds to the average 
and s.e.m. Error bars represent three biological replicates and three technical replicates in 
































Figure 4-2 | Endogenous TCL1 and TCL1b1 showed different expression patterns 
during OSKC-mediated reprogramming. 
16 day-time course expression level of endogenous a, Nanog b, TCL1, and c, TCL1b1 
when OSKC were overexpressed in rtTA MEFs lentivirally. Expresssions were 
normalized against B2M. Data corresponds to the average and s.e.m. Error bars represent 
two biological replicates and three technical replicates in each sample.  
 
4.1.2  TCL1 and TCL1b1 might enhance reprogramming by enhancing AKT1 activity 
Since TCL1 and TCL1b are in the same protein family, it is conceivable that they 
may enhance iPSC reprogramming through similar mechanisms. TCL1 and TCL1b1 are 
cofactors that are known to bind and enhance the kinase activity of Serine/threonine 
kinase AKT1, which in turn potentiates PI3K-AKT1 signaling (Laine et al, 2002; Laine 
et al, 2000). In ESCs, Oct4 regulates TCL1 expression and subsequent AKT1 activity (Hu 
et al, 2008). Furthermore, the overexpression of an active form of AKT1 is able to rescue 
the suppression phenotype on ESCs proliferation by TCL1 knock down (Matoba et al, 
2006).  
The roles of TCL1 and TCL1b1 on AKT1 activity during iPSC reprogramming 
were confirmed when the overexpression of TCL1 and TCL1b1 increased the level of 
active AKT1 protein marked by phosphorylation at Serine 473 in OSK-infected MEFs 
while total AKT1 protein level was unchanged (Figure 4-3a and 4-3b). During the course 
of iPSC reprogramming (16 days), the endogenous AKT1 transcript level was not altered 
(Figure 4-4a). This was supported by the protein expression profile of AKT1 in Figure 4-
3a where the AKT1 levels remained unchanged on 8-dpi and 10-dpi. Interestingly, AKT1 
phosphorylation increased at 10-dpi relative to 8-dpi (Figure 4-3b). More importantly, the 
overexpression of AKT1 in combination with OSK enhanced iPSC reprogamming 
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efficiency by 3-fold (p<0.05) (Figure 4-3c), an effect similar to TCL1 or TCL1b1 
overexpression. However, the cell type specific expression pattern of endogenous AKT1 
was somewhat different from TCL1 and TCL1b1. AKT1 was highly expressed in 





























Figure 4-3 | TCL1 and TCL1b1 enhance reprogramming through phosphorylated 
AKT1. 
Protein level of a, Total AKT1 protein and b, phosphorylated AKT (Ser473) were 
analysed by Western blotting in the MEFs infected with OSK plus indicated lentiviral 
empty vector, TCL1 or TCL1b1 at indicated time points (dpi) . GAPDH was as used as a 
loading control. Data is representative of two independent experiments. c, Fold change of 
reprogramming efficiency of primary Oct4-GFP MEFs retrovirally infected with OSK 



































Figure 4-4 | Expression pattern of endogenous AKT1. 
a, 16 day-time course expression level of endogenous AKT1 when OSKC were 
overexpressed in rtTA MEFs lentivirally. Expresssions were normalized against B2M. 
Data corresponds to the average and s.e.m. Error bars represent two biological replicates 
and three technical replicates in each sample. b, Endogenous expression level of murine 
AKT1 in different cell types. Expression levels were normalized against GAPDH.  Data 
corresponds to the average and s.e.m. Error bars represent three biological replicates and 
three technical replicates in each sample except for ovaries (one biological and three 





4.1.3  PI3K/AKT1 pathway signaling is endogenously required for efficient 
reprogramming  
PI3K signaling has been implicated in the maintenance of mouse and human 
ESCs’ pluripotency (Ding et al, 2010; Niwa et al, 2009; Sato et al, 2003). Given that 
overexpression of multiple components of the PI3K/AKT1 signal transduction pathway 
could reproducibly enhance iPSC cell reprogramming efficiency (AKT1, TCL1, and 
TCL1b1), I investigated whether PI3K/AKT1 pathway signaling is endogenously 
required for the reprogramming of fibroblasts into iPSC cells.  
PI3K/AKT1 signaling was pharmacologically attenuated by adding a PI3K 
inhibitor (LY294002) into the culture media. This led to a 3-fold decrease in 
reprogramming efficiency in wild-type MEFs (Figure 4-5a). Nevertheless, it may be 
questioned whether this reflected a specific requirement for PI3K/AKT1 signaling in 
pluripotent reprogramming, or that the blockade of PI3K/AKT1 signaling (a cardinal cell 
survival pathway) might have simply led to the death of the starting MEFs, and thus 
decreased reprogramming efficiency. Hence, I tested whether p53-/- MEFs that are 
generally refractory to cell death also required PI3K/AKT1 signaling for their 
reprogramming. Again, inhibition of PI3K signaling in these cells led to a significant 
decrease in their reprogramming efficiency and reduced cell growth of infected p53-/- 
MEFs (Figure 4-5).  
AKT1 is a key downstream effector of the PI3K signaling pathway that regulates 
diverse cellular functions, including growth, proliferation, survival, metabolism, motility, 
angiogenesis, and vesicle trafficking (Manning & Cantley, 2007; Vivanco & Sawyers, 
82 
 
2002). To ascertain that TCL1 and TCL1b1 improve iPSC reprogramming efficiency by 
acting as cofactors of AKT1 and directly enhance its activity, a AKT1/2 specific 
chemical inhibitor that inhibit AKT1 kinase activity was used in iPSC experiment. Upon 
overexpression of OSK in Oct4-GFP MEFs, addition of AKT1/2 and AKT1/2/3 
inhibitors decreased the GFP positive iPSC colony number by 10-fold and 5-fold 
respectively (p<0.01) as compared to non-treated control (Figure 4-6a). Furthermore, the 
enhancement effect on iPSC reprogramming by TCL1 and TCL1b1 overexpression was 
significantly suppressed by 60% (p<0.001) and 80% (p<0.01) respectively when AKT1/2 
inhibitor was added (Figure 4-6b).  In addition, the overexpression of TCL1 and TCL1b 

















































Figure 4-5 | Perturbation of the PI3K-AKT1 pathway inhibits reprogramming. 
a, Reprogramming efficiency of OSK-infected p53-/- MEFs and rtTA MEFs with or 
without addition of PI3K inhibitor, LY249002 (10µM). * p<0.05 and ** p<0.01. b, 
Representative images of AP stained colonies, derived from OSK-infected p53-/- MEFs as 
shown in Figure 10a. c, Growth curves of OSK-infected p53-/- MEFs with or without 
addition LY294002. All data correspond to the average and s.e.m. Error bars represent 






























Figure 4-6 | TCL1 and TCL1b1 enhance iPSC reprogramming through AKT1. 
a, Reprogramming efficiency of OSK-infected Oct4-GFP MEFs in untreated culture 
media or with addition of  LY249002 (10µM), AKT1/2 inhibitor (10µM) and AKT1/2/3 
inhibitor (5µM). ** p<0.01. Data correspond to the average and s.e.m. Error bars 
represent three biological replicates in two independent experiments. b, Reprogramming 
efficiency of primary Oct4-GFP MEFs retrovirally infected OSK plus empty vector or 
indicated factor in the absence and presence of AKT1/2 inhibitor (10µM). Data 
correspond to the average and s.e.m. Error bars represent three biological replicates in 
















Figure 4-7 | TCL1 and TCL1b1 overexpression increase cell proliferation rate.  
Growth curves of OSK-infected Oct4-GFP MEFs transduced with additional lentiviral 
empty vector or indicated factor. All data correspond to the average and s.e.m. Error bars 
represent three technical replicates for each sample. 
 
4.1.4  TCL1 may also be involved in AKT1-independent pathway 
The different expression patterns of TCL1 and TCL1b1 appear to suggest that 
TCL1 and TCL1b1 may play different roles during iPSC reprogramming (Figure 7). 
Since TCL1 or TCL1b1 overexpression alone enhance iPSC reprogramming efficiency, I 
sought to examine the effect when both oocyte factors were co-overexpressed. 
Surprisingly, co-overexpression of the two factors significantly further increased the 
reprogramming efficiency by 2-fold (p<0.01) as compared to single factor overexpression 
alone (Figure 4-8a).  In most of the reprogramming assays, defined serum free-KSR was 
used to culture viral infected fibroblasts during the course of reprogramming. 
Interestingly, when ES FBS was used instead for culture, overexpression of TCL1 could 
significantly improve iPSC reprogramming (p<0.05), but the enhancement effect of 
TCL1b1 overexpression was less obvious (Figure 4-8b).  
To ascertain that TCL1 and TCL1b1 share distinct roles in iPSC reprogramming, 
TCL1b1 was overexpressed and checked for its ability to enhance reprogramming 
efficiency when endogenous TCL1 was suppressed. It was observe that AKT1 
overexpression was no longer able to enhance reprogramming efficiency when TCL1 
expression was knocked down. On the contrary, exogenous TCL1b1 rescued the 






































Figure 4-8 | TCL1 may also act on mechanism that is different from TCL1b1.  
a, Reprogramming efficiency of primary Oct4-GFP MEFs infected with OSK plus empty 
vector or indicated factor. Data correspond to the average and s.e.m. Error bars represent 
three technical replicates in three independent experiments. b, Reprogramming efficiency 
of OSK-infected primary Oct4-GFP MEFs reprogrammed in the ESC culture media with 
ESC FBS. c, Reprogramming efficiency of primary wild type MEFs that were infected 
lentivirally with scramble control or shTCL1 followed by infection with retroviral OSK 
plus lentiviral empty vector or indicated factor. All data correspond to the average and 





Interestingly, despite being effective in inhibiting reprogramming efficiency, 
AKT1/2 inhibitor did not completely eliminate the enhancement effect of TCL1 
overexpression. On the other hand, the enhancement effect by TCL1b1 overexpression 
was entirely abolished to the level that was similar to empty vector control (Figure 10b 
and 13a).  To validate the above finding, I used PI3K inhibitor, LY294002 and AKT1/2/3 
inhibitors to test whether the same observation could be derived. Intriguingly, 
overexpression of TCL1, but not TCL1b1, was still able to significantly enhance iPSC 
reprogramming efficiency (0.01<p<0.1) when PI3K-AKT1 pathway or other AKT 





























































Figure 4-9 | TCL1 enhance iPSC reprogramming through AKT1-independent 
pathway.  
Reprogramming efficiency of Oct4-GFP MEFs infected with OSK plus empty vector or 
indicated factor. Reprogramming took place in untreated culture media or with addition 
of LY249002 (10µM), AKT1/2 inhibitor (10µM) and AKT1/2/3 inhibitor (5µM). a, ** 
p<0.01. Data correspond to the average and s.e.m. Error bars represent three technical 
replicates in two independent experiments. b, **p<0.05 and * p<0.1. Data correspond to 







4.2  Discussions 
The expression patterns of TCL1 and TCL1b1 were examined before looking into 
the potential mechanism underlying the enhancement effects of TCL1 and TCL1b in iPSC 
reprogramming (Figure 7). Cell type specific expression results suggest that TCL1 plays 
an important role both in early development and in maintenance of ESC’ self-renewal 
since it was highly expressed in oocyte and ESCs (Figure 7-1) (Ivanova et al, 2006; 
Matoba et al, 2006; Narducci et al, 2002). Furthermore, its expression is known to be 
regulated by two of the reprogramming factors, Oct4 and Klf4 (Matoba et al, 2006; 
Nakatake et al, 2006). Therefore, it is not surprising that such self-renewal marker in 
ESCs was endogenously upregulated during the course of direct reprogramming (Figure 
4-2b). On the other hand, TCL1b1 expression was enriched only in oocytes but not in 
ESCs or fibroblasts thus explaining the observation that endogenous TCL1b1 was not 
upregulated during the course of reprogramming (Figure 7). Different expression patterns 
of endogenous TCL1 and TCL1b1 during the course of reprogramming may suggest that 
different mechanisms are involved for the two oocyte factors.  
AKT1/PKB activity inhibition by AKT1/2 inhibitor is known to be dependent on 
the pleckstrin homology (PH) domain of AKT which is also bound by TC1 and TCL1b 
cofactors (Laine et al, 2002; Zhao et al, 2005). So far, the role of AKT1 signaling in 
reprogramming remains elusive. Studies have shown that activated AKT1 stimulated 
reprogramming in cell fusion experiment but markedly suppressed SCNT when cloned 
embryos were injected (Nakamura et al, 2008). However, another study indicated that 
activated AKT1 promotes cell division and survival in fertilized embryos (Feng et al, 
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2007). To date, the role of AKT1 in factor-mediated direct reprogramming has been 
implicated but has yet to be studied fully (Sanges & Cosma, 2010).  
Here, I showed that overexpression of AKT1 enhanced iPSC reprogramming by 
3-fold (p<0.05) (Figure 4-3c). Interestingly, the level of AKT1 activity increased at a 
later time point suggesting that AKT1 activity was stimulated, probably by endogenous 
TCL1 induced during the course of iPSC reprogramming (Figure 4-1 and 4-3b) since 
knocking down endogenous TCL1 in ESCs reduced the level of phosphorylated AKT1 
(Ser 473) (Matoba et al, 2006). This is further supported by the finding in this study that 
TCL1 overexpression further increased the level of phosphorylated AKT1 (Figure 4-3b). 
Although the AKT1 transcript level was lower in ESCs than in fibroblasts (Figure 4-4b), 
it would still be interesting to examine if the level of phosphorylated AKT1 is higher in 
ESC than in differentiated somatic cells and whether AKT1 activity would be gradually 
enhanced over the course of iPSC reprogramming (e.g. early, middle and late phase). The 
role of AKT1 activity in improving somatic cell reprogramming efficiency can also be 
confirmed if greater enhancement is observed when an active form of AKT1 is 
overexpressed.  
Inhibitor studies (Figure 4-5 and 4-6) suggest that endogenous PI3K/AKT1 
signaling is specifically required for pluripotent reprogramming. One could envisage 
three complementary contingencies that could explain the essential function of 
PI3K/AKT1 signaling in pluripotent reprogramming.  
Firstly (and most parsimoniously), PI3K/AKT1 signaling could just simply be 
essential for the viability of the starting donor fibroblasts or the resultant reprogrammed 
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iPSC cells.  However, this appears unlikely, as p53-/- fibroblasts remained largely viable 
even under PI3K/AKT1 signaling inhibition, and yet they still specifically required 
PI3K/AKT signaling to efficiently reprogram (Figure 4-5c).  
A second possibility is that potentiating PI3K/AKT1 signaling increases cell 
proliferation. Cell proliferation studies with PI3K inhibitor and oocyte factor 
overexpression appeared to suggest that one of the enhancement mechanisms of TCL1 
and TCL1b1 is through potentiating PI3K signaling and subsequent accelerated cell 
proliferation (Figure 4-5c and 4-7) which led to the enhancement of iPSC reprogramming 
in a ‘cell-division-rate-dependent’ mode (Hanna et al, 2009). By accelerating cell 
proliferation, amplified nuclear changes during cell division may facilitate the epigenetic 
marks and allow the re-establishment of the pluripotency transcriptional circuitry (Egli et 
al, 2008; Mikkelsen et al, 2008). In addition, amplification of daughter cells from 
partially reprogrammed cells would also increase the independent probability of each 
daughter cell to become further reprogrammed into iPSC cells.  
The third and very lucrative possibility is that PI3K/AKT1 signaling facilitates 
reprogramming by directly feeding into the “pluripotency transcriptional network” and 
upregulating the expression of specific pluripotency transcription factors to execute 
reprogramming. This is possible, as PI3K/AKT signaling is a subordinate effector of LIF 
signaling in mouse ES cells that specifically upregulates the expression of Tbx3 (Niwa et 
al, 2009; Paling et al, 2004), which itself is known to be essential for undifferentiated ES 
cell self-renewal (Ivanova et al, 2006) and is also known to enhance the developmental 
potential of the resultant iPSC cells (Han et al, 2010). On the other hand, studies have 
also shown that endogenous TCL1 expression was upregulated when LIF was added and 
92 
 
knock down of TCL1 markedly decreased the self-renewal of mouse ESCs,  a phenotype 
that resembles ESCs treated with PI3K inhibitor (Ivanova et al, 2006; Matoba et al, 2006; 
Paling et al, 2004). All these findings appear to suggest that PI3K-AKT1 and TCL1 play 
an important role in maintaining self-renewal of ESCs and they may improve 
reprogramming more than just by accelerating the cell proliferation. Intriguingly, 
inhibition of AKT1 activity significantly suppressed the effects of TCL1 (p<0.001) and 
TCL1b1 (p<0.01) on iPSC reprogramming efficiency, and thus support the hypothesis 
that TCL1 and TCL1b1 augment reprogramming through AKT1 signaling (Figure 4-6b). 
When endogenous TCL1 was suppressed, overexpression of AKT1 failed to enhance 
reprogramming efficiency. However, transgenic TCL1b1, which is another cofactor of 
AKT1, was able to rescue the knock down effect of TCL1. These observations appear to 
suggest that the role of AKT1 in iPSC reprogramming is largely dependent on TCL1 and 
TCL1b1 (Figure 13c). Nevertheless, the redundant roles of TCL1 and TCL1b1 as 
cofactors of AKT1 in iPSC reprogramming merits further investigation.  Clonal 
expression assay shows that the overexpression of TCL1b1, but not TCL1, significantly 
(p<0.001) increased expression level of Nanog in addition to Tbx3 in iPSC clones (Figure 
3-3, in earlier chapter). This appears to suggest that, TCL1b1, a known cofactor of AKT1, 
dominantly potentiates the PI3K-AKT1 pathway that regulates Tbx3 and Nanog 
expression in a hierarchical manner (Niwa et al, 2009). 
Interestingly, when ES FBS was added instead of serum free-KSR into the culture 
media during reprogramming, the enhancement effect of TCL1b1 became insignificant. 
This might be caused by the undesirable increase of ROS production which is detrimental 
to reprogramming when AKT1 signaling was potentiated (Juntilla et al, 2010). Hence, 
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when ascorbic acid which functions to reduce the ROS production was removed, this 
undesirable side effect of AKT1 signaling would reduce the overall enhancement effect 
by TCL1b1.  
The differential expression patterns and susceptibilities to undefined growth 
factors in ES FBS appeared to suggest that TCL1 and TCL1b1 may also be involved in 
different mechanisms apart from AKT1 signaling (Figure 4-1 and 4-8b). This is further 
supported by the significant synergistic effect of co-overexpression of the two oocyte 
factors on iPSC reprogramming enhancement (Figure 4-8a). In the current study, it has 
been validated that the role of TCL1b1 but not TCL1, in iPSC reprogramming, is entirely 
AKT1-activity dependent, as the enhancement effect of TCL1b1 but not TCL1 was 
abolished when different inhibitors of PI3K-AKT1 pathway were used (Figure 13-1). 
AKT1 activity-independent roles of TCL1 have also been described in chronic 
lymphocytic leukemia (Bichi et al, 2002; Gaudio et al, 2012; Pekarsky et al, 2008; Shen 
et al, 2006; Suzuki et al, 2003).  
In this chapter, I have demonstrated that TCL1 and TCL1b1 similarly augmented 
iPSC reprogramming through potentiating the PI3K-AKT1 pathway. There are several 
possible mechanisms that can explain the role of AKT1 signaling in enhancing iPSC 
reprogramming. First, it is known to negatively regulate tumor suppressor p53 by 
enhancing stability and nuclear localization of MDM2, a ubiquitin ligase for p53 (Feng et 
al, 2004; Mayo & Donner, 2001; Zhou et al, 2001). PI3K/AKT1 signaling also inhibits 
the activation of p53 by CHK1/2 during DNA damage response (Hirose et al, 2005; 
Shtivelman et al, 2002). p53 signaling has been shown to block iPSC reprogramming by 
inducing cellular senescence and  DNA damage induced apoptosis (Banito et al, 2009; 
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Hong et al, 2009; Kawamura et al, 2009; Li et al, 2009a; Marion et al, 2009; Utikal et al, 
2009). Second, the PI3K/AKT1 pathway is one of the parallel LIF-Stat3 signaling 
pathways that maintain pluripotency in ESCs (Niwa et al, 2009; Paling et al, 2004). Third, 
AKT1 directly interacts and stabilizes Sox2 binding to the transcriptional machinery that 
eventually enhances somatic cell reprogramming efficiency (Jeong et al, 2010).  Fourth, 
AKT1 is known to phosphorylate and inhibit glycogen synthase kinase 3 (GSK-3) (Cross 
et al, 1995). The inhibition of GSK has been reported to enhance self-renewal of ESCs 
and iPSC reprogramming (Li et al, 2009b; Roberts et al, 2004; Silva et al, 2008). 
Furthermore, the activation of AKT1 signaling is sufficient to maintain the pluripotency 
of ESCs without LIF and feeder cells while inhibition of this pathway by PI3K inhibitor 
LY294002 results in a differentiation even in the presence of LIF (Liu et al, 2009; 
Watanabe et al, 2006). Fifth, AKT1 has been shown to regulate cell metabolism through 
several downstream glycolytic targets (Kohn et al, 1996; Robey & Hay, 0000; Semenza 
et al, 1996; Ueki et al, 1998) and hence may promote metabolic reprogramming during 
iPSC reprogramming (Folmes et al, 2011).   
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CHAPTER 5: PNPASE: A POTENTIAL TARGET OF TCL1 THAT ENHANCEs 
REPROGRAMMING IN A AKT1-INDEPENDENT MANNER 
In the previous chapter, I have shown that TCL1 and TCL1b1 similarly augment 
iPSC reprogramming through activation of AKT1 signaling and that TCL1 is also 
involved in AKT1-independent mechanisms. In this chapter, I shall further explore the 
AKT1-independent role of TCL1 in iPSC reprogramming.   
5.1  Results 
5.1.1  TCL1 interacted with PnPase in primary MEFs 
Since TCL1 also enhances iPSC reprogramming through an AKT1-independent 
pathway, I sought to explore other interacting targets of TCL1 that potentially enhance 
iPSC reprogramming. Besides AKT1, it has been shown recently that TCL1 also binds to 
an exoribonuclease known as Polynucleotide Phosphorylase (PnPase), which plays an 
important role in mRNA processing and mitochondria homeostasis (Chen et al, 2006; 
French et al, 2007). When endogenous expression of PnPase was examined, PnPase was 
expressed at similar levels between pluripotent ESCs and somatic MEFs while its 
expression was higher in ovary (Figure 5-1).  
To ascertain that TCL1 interact with PnPase in primary MEFs upon TCL1 
overexpression, cells were infected with pMX vector carrying hemagglutinin (HA) 
tagged TCL1 and co-immunoprecipitation (co-IP) assay was done with anti-HA and anti-
PnPase. In co-IP with both antibodies, TCL1 was shown to interact with endogenous 
PnPase (Figure 5-2).  The absence of similar interaction bands in IgG co-IP samples and 
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the mitochondrial inner membrane protein, Tim13a/b (Jin et al, 1999) in all co-IP 







Figure 5-1 | Expression patterns of PnPase.  
a, Endogenous expression levels of murine PnPase in different cell types. Expression 
levels were normalized against GAPDH.  Data corresponds to the average and s.e.m. 
Error bars represent three biological replicates and three technical replicates in each 


































Figure 5-2 | TCL1 interacts with PnPase in primary MEFs.  
MEFs were transduced with 3HA-TCL1 tagged pMX-vector. Cell lysates were co-IPed 
with either a, anti-HA or b, anti-PnPase antibodies, resolved by SDS–PAGE, and 
analyzed by immunoblot with anti-HA and anti-PnPase. All results represent data from at 










5.1.2  Knock down of PnPase enhanced iPSC reprogramming  
PnPase expression is upregulated in terminally differentiated melanoma cells and 
in progeroid fibroblasts (Leszczyniecka et al, 2002). Since TCL1 supports proliferation 
and survival (Hoyer et al, 2002; Laine et al, 2000; Pekarsky et al, 2000) while PnPase 
expression is associated with cell senescence (Leszczyniecka et al, 2002), TCL1 may 
interact with PnPase and oppos its function that blocks reprogramming.   
To test this hypothesis, I first sought to examine if knock down of PnPase could 
improve iPSC reprogramming. I constructed lentiviral vectors to express several p53 and 
PnPase small hairpin RNAs (shRNAs), and tested the knockdown efficiency of each 
shRNA lentivirus in MEFs (Figure 5-3). At day 6, transcript expression results showed 
that shRNA1 (shp53-1) construct for p53 resulted in the strongest expression knock down 
of p53 expression (Figure 5-3). Therefore, shp53-1 construct was used as a control in 
iPSC assay for reprogramming enhancement by knocking down p53. Western blotting 
results in Figure 5-3c showed that knocking down p53 with shp53-1 construct completely 
abolished the protein expression of p21, a direct target of p53 (El-Deiry et al, 1994; El-
Deiry et al, 1993). For PnPase shRNA testing, all shRNA constructs showed more than 
30% knock down (Figure 5-3).  The construct that showed the strongest knock down 
(shPnPase-3) was used and knock down efficiency was further confirmed with protein 
expression check. Figure 5-3c showed that PnPase protein expression level was almost 
completely abolished in PnPase knock down sample as compared to scrambled control. 
Strikingly, knock down of PnPase expression resulted in remarkable improvement of 
iPSC reprogramming efficiency by 3-fold in wild type MEFs and 10-fold in p53null 
MEFs (Figure 5-4). Since PnPase is associated with senescence (Leszczyniecka et al, 
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2002), protein level of p21 were measured upon knock down of PnPase. Western blotting 
showed that p21 was increased in PnPase knock down sample as compared to scrambled 























Figure 5-3 | Knock down efficiency of shRNA constructs for p53 and PnPase.  
a, WT MEFs were infected with scrambled shRNA or indicated shRNA followed by 
OSK retroviral transduction. Six days after viral transduction, the transcript expression 
level of a, p53 and b, PnPase were analysed. All expression data correspond to the 
average and s.e.m. Expression levels were normalized against YWHAZ. Error bars 





PnPase were analysed by Western blotting in the MEFs infected with OSK plus 

























































Figure 5-4 | PnPase knock down enhances iPSC reprogramming.   
Fold change of reprogramming efficiency of primary a, wild type (WT) CF1 MEFs and b, 
p53 null MEFs, retrovirally infected with OSK plus indicated shRNAs. Data correspond 
to the average and s.e.m.. Error bars represent three technical replicates in two 
independent experiments. **p<0.01 and ***p<0.001. Below are the representative 
images of AP stained colonies for each cell type. c, Protein level of p21 was analysed by 
Western blotting in the MEFs infected with OSK plus scrambled shRNA or shPnPase-3 
lentivirus. GAPDH was used as a loading control. 
 
5.1.3  PnPase is a downstream target of TCL1 that influences iPSC reprogramming 
efficiency in an AKT1-independent manner 
It is still unclear whether PnPase is a downstream target that is responsible for the 
AKT1-independent role of TCL1.  Next, I sought to examine if TCL1 knock down would 
have any influence on the enhancement effect of PnPase knock down. Results showed 
that TCL1 knock down did not reduce reprogramming efficiency when PnPase was 
knocked down (Figure 5-5). I also tested if PnPase knock down in the presence of 
AKT1/2 inhibitor would reproducibly increase iPSC colony number. Indeed, in the 
presence of AKT1/2 inhibitor (10uM), PnPase knock down was still able to enhance 
iPSC reprogramming efficiency by 4.7-fold (p<0.01) and 14-fold (p<0.001) in wild type 
and p53 null MEFs respectively (Figure 5-6a and 5-6b). The AKT1-independent role of 
PnPase in iPSC reprogramming was further validated when overexpression of AKT1, 
TCL1b1 or TCL1 synergistically enhanced iPSC reprogramming with PnPase knock 






















Figure 5-5 | PnPase is acting downstream of TCL1.  
Fold change of reprogramming efficiency of primary CF1 MEFs, retrovirally infected 
with OSK plus indicated shRNAs. Data correspond to the average and s.e.m. Error bars 

























































Figure 5-6 | Enhancement by PnPase KD is independent of AKT1 activity.  
Fold change of reprogramming efficiency of primary a, wild type CF1 MEFs and b, p53 
null MEFs, retrovirally infected with OSK plus indicated shRNAs. Data correspond to 
the average and s.e.m. Error bars represent three technical replicates in two independent 
experiments. c, Reprogramming efficiency of p53 null MEFs infected with OSK plus 
indicated shRNA in pLL3.7 vector and factor in pLVX-lentiviral vector. Data correspond 
to the average and s.e.m. Error bars represent two biological and three technical replicates 






5.1.4  Endogenous PnPase induction might the cause of poor iPSC reprogramming 
efficiency 
During the course of OSKC-mediated iPSC reprogramming, endogenous PnPase 
was gradually upregulated from Day 10 and onwards (Figure 5-7a). Since PnPase has 
been implicated to maintain mitochondrial homeostasis (Chen et al, 2006), I sought to 
examine the expression patterns of genes that are important for mitochondrial functions. 
Interestingly, the expression level of transcription factor A, mitochondria (TFAM), 
superoxide dismutase 2 (SOD2) and mitochondria RNA polymerase (POLRMT) were 
































Figure 5-7 | Endogenous expression of PnPase was upregulated during the course of 
iPSC reprogramming.  
a, Endogenous expression level of murine PnPase in different cell types. Expression 
levels were normalized against GAPDH.  Data corresponds to the average and s.e.m. 
Error bars represent three biological replicates and three technical replicates in each 
sample except for ovaries (one biological and three technical replicates). b, 16 day-time 
course expression level of endogenous PnPase and c, mitochondrial genes, when OSKC 
were overexpressed in rtTA MEFs lentivirally. Expresssions were normalized against 
B2M. Data corresponds to the average and s.e.m. Error bars represent two biological 




5.2  Discussion 
In addition to well characterized AKT1-TCL1 interaction, PnPase has been 
identified to interact strongly with TCL1 in human leukemic and transformed cell lines 
(French et al, 2007). The present study has proven that the TCL1-PnPase interaction also 
occurred in primary MEFs upon overexpression of HA-tagged TCL1. In addition, TCL1-
PnPase interaction was detected in both forward and reverse Co-IPSC in the present 
study as opposed to where in the previous study, where interaction in reverse Co-IP was 
not detected (French et al, 2007).  
Since TCL1 and PnPase are known to have opposing physiological roles, it is 
conceivable that TCL1 interacts and suppresses the activity of PnPase that inhibits iPSC 
reprogramming. Indeed, the postulated antagonizing role of TCL1 was validated when 
PnPase knock down significantly improved the reprogramming efficiency (Figure 5-4). 
PnPase was also proven to be a downstream target of TCL1 in the context of somatic cell 
reprogramming when it was shown that knock down of TCL1 failed to suppress the 
enhancement effect of PnPase knock down (Figure 5-5). Furthermore, the enhancement 
effect of PnPase knock down remained when AKT1 activity was inhibited and synergistic 
enhancement was observed when PnPase was knocked down in combination with the 
overexpression of each of the players in AKT1 signaling (i.e. AKT1, TCL1b1 and TCL1) 
(Figure 5-6). These findings suggested that the AKT1-independant role of TCL1 in iPSC 
reprogramming could be explained by its inhibition of the activity of PnPase. 
Intriguingly, overexpression of reprogramming factors appeared to upregulate 
undesirably the expression level of endogenous PnPase (Figure 5-7). Such undesirable 
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‘by-products’ of somatic reprogramming is not uncommon. For instance, studies have 
reported that overexpression of Sox2, Klf4 and cMyc upregulates the expression level of 
cyclin-dependent kinase interacting protein, p21, which is known to suppress 
reprogramming through the induction of cellular senescence (Banito et al, 2009). Klf4 is 
also known to inhibit Wnt/beta-catenin signaling that supports somatic reprogramming 
(Evans et al, 2010; Marson et al, 2008; Zhang et al, 2006b).  
Since PnPase knock down has profound effects on iPSC reprogramming and its 
enhancement effect is independent of AKT1 acitivity, the role of PnPase in nuclear 
reprogramming warrants further investigation. It is interesting to observe that the 
enhancement effect of PnPase knock down was stronger when p53 signaling was 
suppressed (Figure 5-4). This can be due to the hindrance of p21-dependent senescence 
that might be induced by PnPase knock down (Figure 5-4c). This observation in fact 
complements the earlier study where overexpression of PnPase decreased p21 protein 
level (Sarkar et al, 2005). Another possibility is that p53 signaling may potentiate the 
‘anti-reprogramming’ role of PnPase and thus in the absence of p53 signaling, the 
enhancement effect by knocking down PnPase became more profound. However, the 
possibility of PnPase knock down efficiency being higher in p53 null MEFs cannot be 
ruled out. 
There are several observations that support the important roles of PnPase in iPSC 
reprogramming. First, the lower mitochondrial copy number and morphology of the cells 
with PnPase knock out resemble one of the features of ESCs and iPSCs (Figure 5-8) 
(Chujo et al, 2012; Wang et al, 2010a). Low mitochondrial activity and a relatively 
under-developed mitochondrial network have been proposed to be indicators of stem cell 
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competence (Cho et al, 2006; Lonergan et al, 2006; Sathananthan et al, 2002). During 
development, there is a progressive decrease in mitochondrial DNA content in the 
blastomeres due to limited mitochondrial DNA replication during cleavage stages 
(Spikings et al, 2007). It has also been shown that nuclear reprogramming induced 
morphological change from elongated and cristae-rich mitochondria of MEFs to spherical 












Figure 5-8 | PnPase knock down causes morphological changes that resemble 
mitochondria in iPSCs.  
Representative images of mitochondrial microscopic structures in a, MEFs and b, iPSCs. 
(Adapted from Folmes et al, Cell Metabolism, 2011) c, Representative images of wild 
type and PnPase-knocked out hepatocytes. Red arrows mark the mitonchondria structures.  






Second, PnPase knock down resulted in accumulation of lactate (Figure 20b), 
which was a phenomenon which resembled that of metabolic reprogramming (Chen et al, 
2006; Folmes et al, 2011). Studies have demonstrated that undifferentiated, pluripotent 
stem cells displayed lower level of mitochondrial mass and oxidative phosphorylation. 
Instead, stem cells preferentially use non-oxidative glycolysis as a major source of energy 
(Armstrong et al, 2010; Prigione et al, 2010). This is further supported by the observation 
that hypoxia is a potent suppressor of mitochondrial oxidation and appears to promote 
“stemness” in adult and mouse ES cells (Ezashi et al, 2005; Prasad et al, 2009; Zhou et al, 
2012). In fact, a recent study has shown that metabolic reprogramming, which involves a 
switch from mitochondrial oxidation to glycolysis, precedes nuclear reprogramming 
(Figure 20a) (Folmes et al, 2011). It has also been proposed that iPSC reprogramming 
efficiency can be enhanced by facilitating a metabolic conversion from mitochondrial 
oxidation to glycolysis during the reprogramming process (Prigione et al, 2010; Zhu et al, 
2010). For instance, p53, which has been shown to substantially improve iPSC 
reprogramming efficiency, plays a role in mitochondria oxidation. Knocking down p53 is 
associated with a metabolic switch away from mitochondrial respiration towards 
glycolysis (Sarkar et al, 2004). Since endogenous PnPase shows a similar expression 
pattern to other mitochondrial proteins during nuclear reprogramming (Figure 18) and 
PnPase knock down compromises mitochondrial function (Chen et al, 2006), it is 
conceivable that knocking down PnPase may facilitate metabolic reprogramming by 
compromising mitochondrial activity and thus resulting in cellular metabolism that favors 
towards glycolysis. The molecular function of PnPase on metabolic reprogramming 
merits further investigation. For instance, Folmes et al. have shown that metabolically 
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reprogrammed cells showed high etramethylrhodamine methyl ester (TMRM) 
fluorescence which was distinguishable from MEFs (low TMRM) (Folmes et al, 2011). It 
would be interesting to examine if PnPase knock down would increase the population of 













Figure 5-9 | PnPase knock down may facilitate metabolic reprogramming.  
a, Schematic diagram showing a metabolic switch from mitochondrial oxidation in MEFs 
to glycolytic pathway in iPSCs during direct somatic cell reprogramming induced with 
overexpression of OSKC. (Adapted from Folmes et al, Cell Metabolism, 2011)  b, 
Schematic diagram showing a metabolic change upon PnPase knock down. (Adapted 






Third, transgenic PnPase increases the production of reactive oxygen species 
(ROS) originating mainly from oxidative phosphorylation in mitochondria (Sarkar et al, 
2004).  A significantly higher amount of ROS was also produced when somatic 
reprogramming is initiated without cMyc and it decreased the reprogramming efficiency 
(Esteban et al, 2010). Therefore, similar to the effect of ascorbic acid, knocking down 
PnPase may enhance reprogramming efficiency by reducing ROS production (Esteban et 
al, 2010).  
In earlier chapters, I have shown that iPSC clones derived with additional TCL1 
overexpression appeared to produce higher Gtl-2 expression (Figure 4-2, in earlier 
chapter). Ascorbic acid, an antioxidant, has been shown to increase significantly the 
reprogramming efficiency and also improve the quality of iPSCs by preventing the loss 
of Gtl-2 expression (Esteban et al, 2010; Stadtfeld et al, 2012). Given these findings, one 
may speculate that TCL1 suppresses PnPase activity, which in turn reduces the 
production of ROS and maintains Gtl-2 expression during the course the iPSC 
reprogramming. Whether PnPase KD would result in iPSC clones with better quality or 
higher Gtl-2 expression awaits further elucidation.  
So far, the role of TCL1 on PnPase activity and how their interactions play a role 
in iPSC reprogramming remain elusive. Since it is unlikely that TCL1 may act directly on 
the enzymatic activity of PnPase (French et al, 2007), an alternate possibility would be 
that TCL1 binding could affect the intracellular localization of PnPase.  This is postulated 
based on the fact that in TCL1-AKT1 interaction, TCL1 binding not only affects the 
activity but also the localization of AKT1 (Pekarsky et al, 2000). To address this, the 
localization of PnPase could be tracked using immunofluorescence staining upon 
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overexpression of TCL1 in MEFs. On the other hand, it still cannot be ruled out that there 
may be other downstream targets that are responsible for the AKT1-independent role of 





CHAPTER 6: CONCLUDING REMARKS 
This thesis has a number of important implications. Firstly, overexpression of two 
oocyte factors, namely TCL1 and TCL1b1, which are from the same protein family, 
augmented factor-mediated iPSC reprogramming – increasing not only the efficiency of 
reprogramming but also the quality of the resultant iPSCs. Secondly, the molecular 
mechanisms underlying the observed enhancements by TCL1 and TCL1b1 were partially 
explained: they appear to enhance AKT1 activity. The roles of AKT1 on suppressing 
anti-reprogramming p53, regulating expression of few pluripotency genes, upregulating 
glycolytic pathway, and enhancing transcriptional activity of reprogramming factor, Sox2, 
were shown in previous studies and these roles appear to explain the observed 
enhancement effect of AKT1 in iPSC reprogramming. Thirdly, TCL1 was also shown to 
augment iPSC reprogramming in a partially AKT1-independent manner and PnPase, a 
mitochondrial protein, was shown to be that AKT1-independent downstream target of 























Figure 6-1 | TCL1 and TCL1b1 enhance the efficiency and quality of iPSC 
reprogramming.  
a, During OSK-mediated reprogramming, endogenous PnPase inhibits while AKT1 
supports iPSC reprogramming. In addition to low reprogramming efficiency, the 
developmental potentials of derived iPSC clones are poor. b, When TCL1 or TCL1b1 are 
overexpressed, AKT1 activity is enhanced and leads to a significant improvement of 
iPSC reprogramming efficiency, partly by p53 inhibition. AKT1 signaling is also 
important for the establishment of pluripotency by enhancing the transcriptional activity 
of Sox2 and regulating the expression of pluripotency genes (i.e. Tbx3 and Nanog). On 
the other hand, TCL1 also modulates PnPase signaling which may cross-talk with p53 
signaling. Modulation of PnPase and AKT1 pathways lead to metabolic changes that 
favor the iPSC reprogramming and increase cell proliferation that facilitates the 





of TCL1 and TCL1b1 on improving the pluripotency and developmental potential of 
iPSC clones have been implicated in this study.  
 
Although TCL1 and TCL1b1 clearly enhance iPSC reprogramming efficiency, 
their effects on reprogramming kinetics and iPSC quality await further investigations. For 
instance, it is still unclear whether the Oct4+SSEA-1- cells exist and mark for fully 
reprogrammed cells in OSK-mediated reprogramming. On the other hand, functional 
validation by tetraploid complementation is necessary to substantiate the roles of TCL1 
and TCL1b1 on the developmental potential of iPSCs. Since the mechanisms by which 
the imprinted RNAs from Dlk1-Dio3 gene cluster are regulated have only begun to be 
explored, further study on how TCL1 and TCL1b1 upregulate the expression from this 
gene locus may shed light on this issue. In spite of the known functional roles of AKT1 in 
other nuclear reprogramming methods, the actual function of AKT1 signaling during 
iPSC reprogramming remains unexplored and therefore it is an interesting area to study. 
It is also important to examine the temporal period (e.g. early or late stage of 
reprogramming) at which TCL1 and TCL1b1 are required to enhance the efficiency in 
iPSC reprogramming. This would determine whether they play a role in the initiation of 
reprogramming or establishment of pluripotency at the late stage of reprogramming. 
Many studies have implicated the roles of PnPase in cancer formation and 
scenescence, however, the role of PnPase in iPSC reprogramming remain unexplored. 
There are three critical research areas regarding PnPase warranting further investigation. 
Firstly, it would be interesting to examine for any cross talks between p53 signaling and 
PnPase since it was envinced that PnPase knock down showed greater enhancement when 
p53 was absent. Secondly, the time course expression results imply that PnPase may 
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correlate with mitochondrial functions and therefore its role in maintaining mitochondrial 
homeostasis creates an interesting target to study with the hope that down regulation of 
PNPase would decrease mitochondrial activity and facilitate a glycolytic shift during 
metabolic reprogramming.  Thirdly, since it has been demonstrated that PnPase regulates 
ROS production, it would be interesting to examine if this explains the influence of 
PnPase on iPSC reprogramming. On the other hand, it is also important to examine the 
role of PnPase knock down on the kinetics and quality of iPSC reprogramming.  
In conclusion, TCL1 and TCL1b1, which are highly enriched in oocytes, are 
shown in the present study to augment iPSC generation by activating multiple pro-
reprogramming pathways. Therefore, TCL1 and TCL1b1 might serve as a mechanistic 






CHAPTER 7: MATERIALS AND METHODS 
7.1  Cell culture and transfection  
All cell cultures were maintained at 37 °C with 5% CO2. GP2-293 (Clontech), 
HEK293FT cells (LifeTech) and MEFs were maintained in DMEM supplemented with 
10% FBS and penicillin/streptomycin. Plat-E packaging cells (Cell Biolabs), which were 
used to produce retrovirus, were maintained according to the manufacturer’s guide. 
Transfection of plasmids into GP2-293, HEK293FT and PLAT-E cells was performed 
using Turbofect (Fermentas). Oct4-GFP (Jackson’s Laboratory, stock no. 004654) and 
rtTA (Jackson’s Laboratory, stock no. 005670) transgenic mice were used for primary 
MEF isolation at E13.5.  p53 null MEFs was obtained with the courtesy of Dr. Philipp 
Kaldis.  
7.2  Plasmid construction 
Full length oocyte factors were amplified from IMAGE cDNA by PCR and cloned into 
pMX vector (Cell Biolabs), Doxicyclin inducible TetO-FUW vector (Addgene) and 
Doxicyclin inducible pLVX-puro vector (Clontech) .  The IMAGE cDNA were human 
TCL1 (Clone ID 3544215), human TCL1b (Clone ID 5813497), human XPG (Clone ID 
3869893), murine TCL1A (Clone ID 30053730), murine TCL1b1 (Clone ID 30053367), 
murine AKT1 (Clone ID 5716837), murine Gadd45a (Clone ID 4035898), murine 
Gadd45b (Clone ID 5355150), murine Gadd45g (Clone ID 3493618), murine Ddx19a 
(Clone ID 3674608), murine Pdia3 (Clone ID 3582199), murine Pdia6 (Clone ID 
2645183), murine OAS1e (Clone ID 30053184), murine Nlrp5 (Clone ID 30049556), 
murine Stk6 (Clone ID 3968835), murine PHB1 (Clone ID 5715690), murine Uhrf1 
118 
 
(Clone ID 4017286), murine Brg1 (Clone ID 40040361), murine PADI6 (Clone ID 
30051727), murine XRCC5 (Clone ID 30008031), murine MSH2 (Clone ID 6401835), 
murine Npm2 (Clone ID 40040361). Murine TCL1 and TCL1b1 were also cloned into 
pMX vector (a kind gift from Dr. Ng Jia Hui, Genome Institute of Singapore, Singapore) 
with the addition of 3×HA epitopes.  
For construction of plasmids for shRNA synthesis, 21 base-pair gene-specific RNAi 
regions were designed based on algorithm  created by Reynolds et al. (Reynolds et al, 
2004). Synthetic oligos were then cloned into pLL3.7-GFP vector (Addgene plasmid 
11795). Four shRNAs were designed to target each gene. All sequences were analyzed by 
BLAST to ensure specificity. See Appendix 2 for sequences. 
7.3  Murine iPSC reprogramming assay and drug treatment 
Reprogramming of primary MEFs (passage 2) was performed following modification of 
previous protocol (Takahashi & Yamanaka, 2006). In brief, viral supernatant, produced 
in PLAT-E cells transfected with Oct4, Sox2 and Klf4 in pMXs vector (Addgene), was 
added to MEFs that were seeded 24 hours earlier (1x105 cells/ml).  After 24-hour 
infection, retrovirally infected MEFs were infected again with lentiviral supernatant. 
Lentiviral supernatant was harvested from HEK293FT cells transfected with pLVX-Tet-
On Advanced (Clontech)/FUW-M2rtTA (Addgene), together with packaging vectors 
pCMV-delta-8.2 (Addgene) and pCMV-VSV-G. This was followed by another round of 
lentiviral infection with supernatant harvested by transfection of HEK293FT cells with 
oocyte factors cloned in pLVX-puro/TetO-FUW vectors and corresponding packaging 
vectors. After 24-hour infection, fresh media was added. Infected wild type and p53 null 
MEFs were replated, at 1x104cells/ml and 2.5x103cells/ml respectively, onto inactivated 
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MEFs feeder on the following day. For MEFs that were infected with pLVX-puro vector, 
2.5ug/ml puromycin was added into the media for 3 days before cell replating. One day 
after replating, cells were maintained in mouse ES media containing doxicyclin (Dox) 
with daily medium change. Colony counting was performed after 16days. For the OSKC-
mediated reprogramming, rtTA MEFs were infected with lentiviral supernatant harvested 
by transfection with TetO-FUW-OSKC (Addgene) as described previously (Carey et al, 
2008). The total number of iPSC cell colonies was counted based on Oct4-GFP positive 
colonies or after staining plates for alkaline phosphatase activity (AP detection kit, 
Chemicon International) following the manufacturer’s instructions. LY294002 (Sigma, 
10uM), AKT1/2 inhibitor (Sigma, 10uM) and AKT1/2/3 inhibitors were added into the 
culture media one day after replating of infected MEFs onto feeders until the day of 
colony counting. 
7.4  shRNA-mediated knock down  
After one day of seeding, MEFs was infected with lentiviral supernatant produced in 
293FT cells that were transfected with shRNA constructs in pLL3.7 vectors, together 
with packaging vectors pCMV-VSV-G (Addgene), pMDLg/pRRE (Addgene) and pRSV-
Rev (Addgene). Two days after infection, cells were sorted for GFP positive using BD 
FACS Aria II cell sorter and seeded for iPSC reprogramming assay on the next day.  
7.5  Feeder free human iPSC reprogramming assay  
Viral supernatant was produced in GP2-293 transfected with Oct4, Sox2 and Klf4 in 
pMXs vector (Addgene) and added onto human dermal fibroblasts (Pormocell) that were 
seeded 24 hours earlier (1x105/ml).  After 24-hour infection, retrovirally infected 
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fibroblasts were infected again with lentiviral supernatant. Lentiviral supernatant was 
harvested from HEK293FT cells transfected with pLVX-Tet-On Advanced (Clontech) 
and pLVX-puro-TCL1/TCL1b1 together with packaging vectors pCMV-delta-8.2 
(Addgene) and pCMV-VSV-G (Addgene). After 24-hour infection, fresh media with 
2.5ug/ml puromycin was added. After 3 days of puromycin selection, infected fobroblasts 
were replated at (2.4x104 cells/ml) onto matrigel-coated wells. One day after replating, 
cells were maintained in chemically defined mTeSR medium (Stem Cell Technologies) 
containing doxicyclin (Dox) with daily medium change. After 21days, total number of 
iPSC cell colonies was counted based on colonies stained positive for Tra-1-60 and AP. 
7.6  Genomic DNA isolation, PCR and analysis of transgene integration 
Genomic DNA was isolated and column-purified with DNeasy Blood & Tissue Kit 
(Qiagen). PCR was set up using HiFi PCR kit (KAPA Biosystems) with designed primers 
and run on thermal cycler (Biorad). See Appendix 1 for PCR primers.  
7.7  RNA isolation, real-time PCR, and analysis of transcript levels 
For the whole cell population expression study, RNA was extracted using Trizol 
(Invitrogen) and column-purified with RNeasy kits (Qiagen). First strand cDNA was 
synthesized using the Superscript First Strand Synthesis System (Invitrogen) at 37 °C for 
2 h. The synthesized cDNA was diluted 20-fold. SYBR green QPCR was performed 
using an Applied Biosystems (ABI) 7960HT sequence detector. Expression was analyzed 
relative to the GAPDH, B2M, YWHAZ mRNA, whichever is the most stable. See 




7.8  Single colony expression assay 
Mature Oct4-GFP positive iPSC colonies were picked and trypsinized into single cells. 
Cells were then lysed and purified using a PicoPure RNA isolation kit (Life Tech).  
cDNA was synthesized with Cell Direct qRT-PCR kit (Life Tech). The sequence specific 
reverse transcription was performed at 50°C for 20 min. The reverse transcriptase was 
inactivated by heating to 95°C for 2 min which was followed by sequence-specific 
amplification by denaturing at 95°C for 15 s, and amplification at 60°C for 4 min for 
18 cycles. The pre-amplified products were diluted 5-fold. Expression assay was done 
with universal master mix and inventoried Taqman gene expression assays (ABI) in 
96.96 Dynamic Array on a BioMark System (Fluidigm). Taqman probes for the 
housekeeping gene GAPDH (ABI, Mm99999915_g1) as a normalization control and 
genes of interest were Oct4 (ABI, Mm00658129_gH), Nanog (ABI, Mm02019550_s1), 
GTL2 (ABI, Mm00522599_m1), Rian (ABI, Mm01325844_m1), Tbx3 (ABI, 
Mm01195726_m1), Dlk1 (ABI, Mm00494477_m1), Rex1 (ABI, Mm03053975_g1), 
Ct values were calculated with the system's software (BioMark Real-time PCR Analysis; 
Fluidigm) and analyzed with GraphPad Prism software. Colony expression assay was 
also done with cDNA directly converted from picked iPSC colonies using Cell Direct 
qRT-PCR kit. The cDNA was diluted 10-fold. Taqman expression assay (ABI) was 




7.9  Protein extraction and Western blotting 
To obtain protein extracts, cells were trypsinized, centrifuged at 450 x g for 5min at 4 ºC, 
washed in chilled PBS, and incubated in chilled lysis buffer for 20min. Protease 
inhibitors (Roche) were freshly added into the lysis buffer. Lysates were then cleared by 
centrifugation at 12,100 × g, 4 ºC for 15 min. The concentrations of supernatants were 
determined using Bradford Dye (Biorad). 40ug of total protein lysates were separated by 
SDS-PAGE on NuPAge gels (Life Tech), and transferred to Hybond-P PVDF membrane 
(GE Healthcare). The membranes were probed with specific antibodies: GAPDH, (Santa 
Cruz SC137179), p53 (Santa Cruz SC126), PnPase (Santa Cruz SC 365049), p21 (Santa 
Cruz SC397),  phosphoAKT1 (Ser473) (Cell Signaling) and antibody-protein complexes 
were detected by HRP-conjugated antibodies and ECL-Plus (Amersham Biosciences). 
7.10  Co-immunoprecipitation (co-IP) 
Cells were lysed with protein lysis buffer (1% Triton X-100, 150 mM NaCl, 20 mM Tris-
HCl pH8.0, 1 mM sodium vanadate, 10 mM sodium fluoride, Roche protease inhibitor 
tablet) and cleared by centrifugation at 15,000 rpm at 4 °C for 10 minutes. The supernatants 
were transferred to clean eppendorf tubes and pre-cleared with 30ul Protein A/G 
Sepharose beads (Roche) for 6 hours. After centrifuging samples at 12krcf for 30 seconds, 
supernatants were transferred to clean eppendorf tubes. 2ug of specific primary 
antibodies were added and samples were rotated overnight at 4ºC. 25ul Protein A/G 
Sepharose beads were added and further incubated for 1 hour. After centrifuging samples 
at 12krcf for 30 seconds, beads were washed once with protein Lysis buffer, followed by 
washing with buffer 2 (50mM Tris-HCl pH7.4, 500mM NaCl, 0.05% sodium 
deoxycholate, 0.1% Igepal CA630) and then buffer 3 (50mM Tris-HCl pH7.4, 0.05% 
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sodium deoxycholate, 0.1% Igepal CA630). Immunoprecipitates were eluted with SDS 
loading buffer and analysed with Western Blotting. Anti-HA (Santa Cruz SC805), anti-
PnPase (Santa Cruz SC99006) and non-specific IgG (Santa Cruz SC2027) were used for 
the co-IP assay. 
7.11  Fluorescence-activated cell sorting 
Cell were trypsinized at indicated time points, isolated into uniform single-cell 
suspension using cell strainer (BD Biosciences), centrifuged at 450 x g for 5min at 4 ºC 
and then fixed with chilled 0.5% PFA for 15min. After centrifugation, cells were washed 
twice with chilled PBS. Staining was done with anti-SSEA1 (Millipore) and Alexa647 
anti-mouse IgG. Stained cells were then analysed for Oct4-GFP positive and SSEA1 
positive cells in population of 50,000 cells using Becton Dickinson LSRII Flow 
Cytometry Analyser.  
7.12  Immunofluoresnce and alkaline phosphatase (AP) staining 
Cells were fixed in 4% paraformaldehyde for 15 min at room temperature. After 1x PBS 
wash, the cells were blocked in 3% BSA (GIBCO) for 30 min at room temperature and 
subsequently stained with anti-Oct4 (Santa Cruz, 200ng/ml), anti-SSEA-1 (Millipore 
1:1000 dilution), anti-Nanog (Santa Cruz, 200ng/ml) anti-TRA-1-60 (Santa Cruz, 
200ng/ml). After overnight incubation at 4⁰C followed by 3x PBS washes, Alexa Fluor 
488 Goat anti-mouse IgG (Life Tech, 2ug/ml) was added and stained for an additional 30 
min. Following 3x PBS washes, staining with Hoechst for 5min. AP staining (Millipore) 
was carried out according to manufacturer’s recommendation. Cells were imaged and 
colonies were counted using Carl Zeiss Axio Observer microscope.  
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7.13  Statistical analysis  
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List PCR primers for genomic integration check for transgenes 
 
Vectors Forward Reverse 
pMX-mOct4 GACGGCATCGCAGCTTGGATACAC CCAATACCTCTGAGCCTGGTCCGAT 
pMX-mSox2 GACGGCATCGCAGCTTGGATACAC GCTTCAGCTCCGTCTCCATCATGTT 
pMX-mKlf4 GACGGCATCGCAGCTTGGATACAC CGTGGAGAAGGACGGGAGCAGAG 




List of shRNA oligos 
 




























































































List of Quantitative PCR Primers 

























B2M Mouse CACCCGCCTCACATTGAAAT TCGATCCCAGTAGACGGTCTT 
TCL1b Human CGGATTCCAGTTTCTGGGAAA ACCAGCTGCTCCATAGAGTCAAT 
TCL1 Human CCAGTTTCTGGCGCTTAGTGT TCCACGCCGTCAATCTTGATG 










    
    
  
 
